

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	levocarnitine	Carnitor	11/15/1989	1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity	Sigma-Tau Pharmaceuticals, Inc.
2	thalidomide	n/a	9/19/1988	1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation	Pediatric Pharmaceuticals, Inc.
3	Theranost 68 Ga RGD	n/a	10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Advanced Imaging Projects, LLC (AIP)
4	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
5	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
6	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
7	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
8	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
9	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
10	clenbuterol	Spiropent, Ventipulmin	10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Duke University Medical Center
11	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
12	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
13	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
14	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
15	selumetinib	n/a	5/10/2016	Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.	AstraZeneca Pharmaceuticals LP
16	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
17	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole	n/a	1/6/2016	As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma.	Advanced Imaging Projects, LLC
18	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
19	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
20	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, Inc.
21	polyinosinic-polycytidilic acid	Poly-IcIc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
22	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administering penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC
23	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
24	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
25	treosulfan	n/a	4/8/2015	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Medac GmbH
26	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
27	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.
28	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
29	OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	On Target Laboratories, LLC
30	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
31	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
32	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
33	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
34	theranost 68Ga-RGD	n/a	12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Advanced Imaging Projects, LLC
35	1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole (18F-Misonidazole)	n/a	4/6/2016	Diagnostic for management of glioma.	Advanced Imaging Projects, LLC
36	Gallium (68Ga) edotreotide	Somakit Toc	7/1/2015	Diagnostic for the clinical management of neuroendocrine tumors.	Advanced Accelerator Applications, USA
37	Theranost 68Ga RGD	n/a	1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Advanced Imaging Projects, LLC
38	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
39	florilglutamic acid	n/a	5/11/2016	Diagnostic for the management of glioma	Piramal Imaging S.A.
40	[F18] florilglutamic acid	n/a	7/13/2016	Diagnostic for the management of hepatocellular carcinoma	Piramal Imaging S.A.
41	chlorotoxin conjugated to indocyanine green dye	n/a	6/23/2015	Diagnostic for the management of malignant brain tumors	Blaze Bioscience, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
42	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
43	Copper 64-DOTA-TATE	Netmedix (Tm)	5/18/2016	Diagnostic for the management of neuroendocrine tumors.	RadioMedix, Inc.
44	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
45	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
46	18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane	n/a	1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Advanced Imaging Projects, LLC
47	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
48	human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000	n/a	6/2/2016	Enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant.	Taiga Biotechnologies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
49	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
50	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.
51	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
52	estradiol Gel	n/a	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC
53	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
54	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
55	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
56	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.
57	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation
58	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.
59	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
60	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
61	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
62	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
63	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Horizon Therapeutics, Inc.
64	(3S)-3-[(1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl)amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt	n/a	4/25/2016	For mobilization of hematopoietic stem cells	Aviara Pharmaceuticals, Inc/
65	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
66	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
67	Anthrax Vaccine Adsorbed	Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent BioDefense Operations Lansing LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
68	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
69	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
70	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
71	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.
72	andexanet alfa	n/a	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Portola Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
73	lobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC
74	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
75	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
76	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
77	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
78	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
79	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
80	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
81	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
82	fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)	n/a	4/7/2015	For the diagnosis of glioma	Blue Earth Diagnostics Ltd.
83	[F18] florilglutamic acid	n/a	7/13/2016	For the diagnosis of hepatocellular carcinoma	Piramal Imaging S.A.
84	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
85	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
86	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
87	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
88	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
89	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
90	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
91	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
92	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
93	methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts	Therakos, Inc.
94	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
95	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Jazz Pharmaceuticals, Inc.
96	Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
97	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
98	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Clinigen Group plc
99	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.
100	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
101	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.
102	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
103		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd
104	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
105	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
106	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	1/7/2015	For the treatment of Cushing's Syndrome	Millendo Therapeutics, Inc.
107	p1-(uridine 5')-p4-(2'-deoxycytidine 5')-tetrphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.
108	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Zogenix, Inc.
109	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
110	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
111	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
112	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
113	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Columbia University Medical Center
114	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.
115	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development
116	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
117	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	12/29/2015	For the treatment of severe preeclampsia	Pluristem Therapeutics, Inc

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
118	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.
119	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
120	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
121	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
122	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
123	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Castle Creek Pharmaceuticals, LLC
124	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
125	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
126	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Clinigen Group plc
127	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Clinigen Group plc
128	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogenic hematopoietic stem cell transplantation	Pharmalink AB
129	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
130	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
131	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
132	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Nikkiso America, Inc.
133	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
134	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
135	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
136	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
137	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
138	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
139	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
140	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
141	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
142	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
143	paclitaxel-coated buttress	n/a	7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	AcuityBio, Inc.
144	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
145	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
146	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
147	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
148	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
149	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
150	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
151	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
152	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
153	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
154	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)glutaminy-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
155	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
156	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
157	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
158	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
159	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
160	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
161	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Innovate Biopharmaceuticals, Inc.
162	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
163	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
164	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
165	Methoxsalen	Uvadex	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.
166	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
167	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, LLC
168	cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer	Allergan, Inc.
169	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
170	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
171	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
172	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
173	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD
174	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
175	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
176	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
177	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
178	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
179	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
180	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
181	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
182	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
183	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut
184	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation
185	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
186	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
187	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
188	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
189	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteiny-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteiny-L-agine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
190	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Novartis Pharmaceuticals Corporation
191	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
192	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
193	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.
194	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
195	Interleukin-2	Teceleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
196	Interleukin-2	Teceleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
197	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
198	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
199	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
200	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
201	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
202	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
203	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
204	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
205	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
206	adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine	n/a	6/8/2015	Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	PNP Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
207	Acetylcysteine	Mucomyst/Mucomyst 10 Iv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
208	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
209	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Abbott
210	diazepam (intranasal)	n/a	11/16/2015	Management of acute repetitive seizures.	Neurelis Pharmaceuticals, Inc.
211	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
212	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
213	S-nitrosoglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMAceuticals, LLC
214	amikacin sulfate	n/a	1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PlumeStars s.r.l.
215	68G-OPS202, small somatostatin analog labeled with 68Gallium	n/a	9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors.	OctreoPharm Sciences GmbH

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
216	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
217	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
218	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
219	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
220	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
221	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
222	telotristat etiprate	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
223	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC
224	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
225	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
226	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
227	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.
228	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
229	Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies	n/a	10/7/2015	Post-exposure prophylaxis against rabies virus infection	Synermore Biologics Co., Ltd
230	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
231	Antithrombin III human	Antithrombin Iii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
232	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
233	allogeneic hematopoietic stem cell	Atir	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
234	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
235	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
236	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
237	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.
238	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
239	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	Alan L. Buchman, MD, MSPH
240	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
241	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
242	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
243	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
244	3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	BioCryst Pharmaceuticals, Inc.
245	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.
246	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
247	recilisib sodium	Ex-Rad(R)	6/1/2012	Prevention of acute radiation syndrome	Onconova Therapeutics, Inc.
248	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
249	immunoglobulin G degrading enzyme of Streptococcus pyogenes	n/a	9/10/2015	Prevention of antibody mediated organ rejection in solid organ transplant patients.	Hansa Medical AB
250	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
251	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire
252	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
253	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
254	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
255	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
256	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
257	recombinant human surfactant protein D	n/a	6/23/2014	Prevention of bronchopulmonary dysplasia	Airway Therapeutics LLC
258	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Windtree Therapeutics, Inc.
259	Retinol palmitate	n/a	8/8/2016	Prevention of bronchopulmonary dysplasia.	Phillipp Heinrich Novak, DVM, MSc

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
260	vitamin A palmitate	n/a	7/14/2015	Prevention of bronchopulmonary dysplasia.	Advent Therapeutics, Inc.
261	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
262	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Therapeutics, Inc.
263	dexrazoxane hydrochloride	n/a	8/19/2014	Prevention of cardiomyopathy for children and adolescents 0 through 16 years of age treated with anthracyclines	Satiscor, LLC
264	ondansetron inhalation powder	n/a	10/14/2015	Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .	Luxena Pharmaceuticals, Inc.
265	glucagon infusion	G-Pump (Tm)	9/25/2014	Prevention of chronic, severe hypoglycemia related to congenital hyperinsulinism	Xeris Pharmaceuticals, Inc.
266	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
267	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
268	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
269	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Santen SAS
270	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
271	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
272	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.
273	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
274	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
275	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
276	glycylafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
277	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
278	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
279	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
280	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
281	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
282	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
283	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylis Pharma AS
284	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
285	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
286	low molecular weight dextran sulfate	lbsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB
287	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
288	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
289	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
290	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
291	cannabidiol	n/a	7/14/2015	Prevention of Graft versus Host Disease (GVHD).	Talent biotech Ltd.
292	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
293	2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl]thio]phenyl]ethyl]1,3-propanediol hydrochloride	n/a	10/6/2015	Prevention of graft versus host disease.	Novartis Pharmaceuticals Corporation
294	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
295	vedolizumab	n/a	8/4/2016	Prevention of graft versus host disease.	Millennium Pharmaceuticals, Inc.
296	liposomal α -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
297	recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain	n/a	6/9/2015	Prevention of graft-versus-host disease	Oncolmmune, Inc.
298	recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/2014	Prevention of graft-vs-host disease	SciVac Ltd.
299	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army
300	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
301	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
302	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
303	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
304	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
305	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure and unexplained recurrent miscarriage	Nora Therapeutics, Inc.
306	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
307	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-Laspararginy]-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated with solid organ transplantation	Endotis Pharma
308	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
309	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
310	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico Forschung und Entwicklung GmbH
311	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
312	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
313	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.A.
314	cardiotrophin-1	n/a	10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Digna Biotech, S.L.
315	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
316	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.
317	bovine lactoferrin	n/a	2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Metrodora Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
318	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
319	Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	n/a	3/24/2015	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Sigma-Tau Pharmaceuticals, Inc.
320	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics
321	bovine lactoferrin	n/a	2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Metrodora Therapeutics, LLC
322	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Therabron Therapeutics, Inc.
323	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
324	somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.	n/a	2/4/2016	Prevention of organ rejection in living donor kidney transplant recipients	Novartis Pharmaceuticals Corporation
325	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
326	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
327	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
328	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Fennec Pharmaceuticals, Inc.
329	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
330	N-acetylcysteine and sodium thiosulfate	n/a	8/31/2015	Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).	Edward A. Neuwelt, MD
331	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
332	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease	Fisons Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
333	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
334	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
335	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
336	17-a-hydroxyprogesterone caporate (oral formulation)	n/a	6/1/2015	Prevention of preterm birth in women with a singleton pregnancy	Lipocine, Inc.
337	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
338	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
339	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
340	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Meda AB
341	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
342	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
343	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
344	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
345	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
346	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
347	4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid	n/a	3/24/2015	Prevention of scarring post ab externo glaucoma surgery	Clanotech AB

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
348	synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA	n/a	6/4/2014	Prevention of scarring post glaucoma filtration surgery	Isarna Therapeutics GmbH
349	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
350	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxalta US Inc.
351	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
352	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
353	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
354	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming Group N.V.
355	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
356	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
357	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
358	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
359	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
360	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.
361	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
362	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
363	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
364	5GAATATTAACAIACTGACAAGT C-3	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
365	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.
366	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
367	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
368	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
369	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
370	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
371	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
372	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
373	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
374	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
375	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
376	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
377	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
378	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.
379	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
380	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.
381	dodecafluoropentane emulsion (DDFPe)	n/a	12/2/2015	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).	NuvOx Pharma
382	ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose)	n/a	5/19/2016	Radiosensitizer to be used during radiation treatment of glioblastoma multiforme.	EMEK, Inc.
383	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
384	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
385	CaspaCIDE System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid	n/a	2/18/2016	Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant	Bellicum Pharmaceuticals, Inc.
386	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
387	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
388	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
389	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
390	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease)	Novo Nordisk, Inc.
391	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
392	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
393	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
394	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
395	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
396	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
397	Gallium-68 (DOTA0-Phe1-Tyr3)octreotide	n/a	10/25/2013	The management of neuroendocrine tumors	University of Iowa Hospital & Clinics

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
398	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC
399	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
400	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
401	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia) in hematopoietic stem cell transplants.	US Biotest, Inc.
402	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
403	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
404	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
405	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
406	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
407	xenon gas	n/a	5/18/2015	To improve neurological outcome in hospitalized cardiac arrest patients.	Neuroprotexon
408	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
409	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
410	refanalina	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
411	recombinant human fucosyltransferase VI [FTVI] + GDP-fucose	n/a	1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	TargaZyme, Inc.
412	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
413	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
414	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
415	inBreath airway transplant system	n/a	9/4/2014	To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection	Biostage, Inc.
416	Brilliant Blue G	Dorc Ilm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
417	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
418	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
419	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
420	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
421	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC
422	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
423	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
424	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)
425	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
426	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
427	everolimus ointment	n/a	9/10/2015	Topical treatment of Tuberous Sclerosis Complex-related skin lesions	Aucta Pharmaceuticals, LLC
428	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
429	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
430	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
431	evinacumab	n/a	2/8/2016	Treatment of homozygous familial hypercholesterolemia.	Regeneron Pharmaceuticals, Inc.
432	budesonide	Uceris	5/6/2013	Treatment of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
433	folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val	n/a	6/8/2016	Treatment (including prevention of recurrence) of ovarian cancer	Galena Biopharma, Inc.
434	Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val	n/a	6/8/2016	Treatment (including prevention of recurrence) of ovarian cancer	Galena Biopharma, Inc.
435	Cyclo {(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
436	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
437	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
438	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
439	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
440	Mefloquine HCl	Mephaquin	7/22/1987	Treatment and prevention of chloroquine-resistant Falciparum malaria	Mepha AG
441	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation
442	long acting recombinant Factor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
443	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
444	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
445	Lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
446	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
447	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.
448	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
449	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen, Inc.
450	tri-antennary glycotriptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
451	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
452	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
453	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
454	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD
455	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
456	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
457	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc
458	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
459	temozolomide	n/a	11/25/2015	Treatment glioblastoma multiforme in pediatric patients	AmpliPharm Pharmaceuticals, LLC
460	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Array BioPharma, Inc.
461	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
462	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Prothena Therapeutics Limited
463	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
464	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3)	n/a	11/16/2015	Treatment of achromatopsia caused by mutations in the CNGA3 gene	Applied Genetic Technologies Corp.
465	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
466	adenovirus associated viral vector serotype 8 containing the human CNGB3 gene	n/a	3/10/2016	Treatment of achromatopsia due to mutations in the CNGB3 gene.	MeiraGTx Limited
467	olipudase alfa	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
468	2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide	n/a	5/10/2016	Treatment of acromegaly	Antisense Therapeutics Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
469	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
470	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
471	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.
472	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
473	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
474	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	4D Pharma Research Ltd
475	filociclovir	n/a	11/29/2010	Treatment of active cytomegalovirus infections	Microbiotix, Inc.
476	clofazimine	Lamprene	6/25/2014	Treatment of active tuberculosis	Novartis Pharmaceuticals Corp.
477	Substituted imidazopyridine amide	n/a	12/22/2015	Treatment of active tuberculosis (TB).	Qurient Co., Ltd.
478	Tretinoin	Atra-lv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
479	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
480	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
481	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
482	N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	n/a	11/17/2014	Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)	Emergent Virology, LLC
483	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.
484	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
485	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
486	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
487	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
488	Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide targeting delta-aminolevulinic acid synthase 1	n/a	8/29/2016	Treatment of acute hepatic porphyria	Alnylam Pharmaceuticals
489	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Fera Pharmaceuticals
490	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
491	recombinant human porphobilinogen deaminase, erythropoietic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	Zymenex A/S
492	Histreltin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D.
493	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
494	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
495	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amliel-Lefond, MD
496	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
497	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
498	poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics Inc.
499	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure	Digna Biotech S.L.
500	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
501	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.
502	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
503	bortezomib	Velcade	2/3/2015	Treatment of acute lymphoblastic leukemia	Millennium Pharmaceuticals, Inc.
504	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
505	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
506	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
507	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
508	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
509	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Juno Therapeutics, Inc.
510	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
511	autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	11/6/2014	Treatment of acute lymphoblastic leukemia (inclusive of B-cell acute lymphoblastic leukemia)	Juno Therapeutics, Inc.
512	methotrexate oral solution	n/a	5/28/2015	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Silvergate Pharmaceuticals, Inc.
513	methotrexate oral liquid formulation	n/a	3/18/2015	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Chesapeake Therapeutics
514	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd
515	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
516	Ruxolitinib	n/a	7/18/2016	Treatment of acute lymphoblastic leukemia.	Incyte Corporation
517	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of acute lymphoblastic leukemia.	Gamida Cell Ltd.
518	Autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of acute lymphoblastic leukemia. (ALL).	Kite Pharma, Inc.
519	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta, Inc.
520	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
521	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
522	225Ac-lintuzumab	n/a	11/25/2014	Treatment of acute myelogenous leukemia	Actinium Pharmaceuticals, Inc.
523	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
524	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	Mateon Therapeutics, Inc.
525	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
526	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
527	isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/2014	Treatment of acute myelogenous leukemia	Celgene Corporation
528	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
529	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.
530	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
531	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
532	humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47	n/a	8/20/2015	Treatment of acute myeloid (myelogenous) leukemia.	Forty Seven, Inc.
533	(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine	n/a	11/5/2014	Treatment of acute myeloid leukemia	BerGenBio AS
534	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
535	2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline	n/a	6/1/2015	Treatment of acute myeloid leukemia	Aptose Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
536	2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate	n/a	7/16/2014	Treatment of acute myeloid leukemia	OncoEthix SA
537	2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
538	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidiny]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
539	4-[[{(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
540	allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells	n/a	4/20/2016	Treatment of acute myeloid leukemia	IPD-Therapeutics BV

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
541	alvocidib	n/a	4/21/2014	Treatment of acute myeloid leukemia	Tolero Pharmaceuticals, Inc.
542	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
543	antroquinonol	Hocena(R)	4/30/2015	Treatment of acute myeloid leukemia	Golden Biotechnology Corporation
544	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
545	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
546	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
547	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
548	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
549	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
550	human fully IgG1 antibody specific for CD33	n/a	6/19/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
551	Human Wilms tumor protein 1 peptides	n/a	12/23/2015	Treatment of acute myeloid leukemia	SELLAS Life Sciences Group

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
552	humanized monoclonal antibody that targets the α-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	n/a	5/5/2015	Treatment of acute myeloid leukemia	Janssen Research & Development, LLC
553	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.
554	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
555	Liposomal annexin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
556	liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	n/a	4/27/2015	Treatment of acute myeloid leukemia	Bio-Path Holdings, Inc.
557	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
558	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
559	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	Mirati Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
560	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Daiichi Sankyo Pharma Development
561	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
562	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.
563	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
564	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
565	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.
566	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
567	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/15/2013	Treatment of Acute Myeloid Leukemia	Epizyme Inc.
568	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.
569	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	CTI BioPharma Corporation
570	ulocuplumab	n/a	1/12/2015	Treatment of acute myeloid leukemia	Bristol-Myers Squibb Company
571	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
572	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
573	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
574	131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I)	n/a	3/28/2016	Treatment of Acute Myeloid Leukemia (AML)	Actinium Pharmaceuticals, Inc.
575	E-selectin antagonist	n/a	5/13/2015	Treatment of acute myeloid leukemia (AML)	GlycoMimetics, Inc.
576	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
577	isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor	n/a	6/9/2015	Treatment of acute myeloid leukemia (AML)	Agios Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
578	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
579	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.
580	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
581	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminy-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylnaide disulfide	n/a	11/24/2015	Treatment of acute myeloid leukemia.	Genus Oncology, LLC
582	echinomycin	n/a	5/21/2015	Treatment of acute myeloid leukemia.	OncolImmune, Inc.
583	guadecitabine	n/a	9/29/2015	Treatment of acute myeloid leukemia.	Astex Pharmaceuticals, Inc.
584	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
585	inecalcitol	n/a	8/3/2015	Treatment of acute myeloid leukemia.	Hybrigenics, S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
586	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Trillium Therapeutics, Inc.
587	vadastuximab talirine	n/a	11/10/2015	Treatment of acute myeloid leukemia.	Seattle Genetics, Inc.
588	venetoclax	n/a	2/4/2016	Treatment of acute myeloid leukemia.	AbbVie Inc.
589	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leukemia	MEI Pharma Inc.
590	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.
591	dalbavancin	Dalvance	3/30/2015	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Durata Therapeutics International B.V.
592	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
593	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
594	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
595	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
596	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
597	arsenic trioxide capsule (oral)	n/a	11/2/2015	Treatment of acute promyelocytic leukemia.	Orsenix Holdings BV
598	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
599	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
600	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
601	recilisib sodium	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
602	recombinant human interleukin-12	Hemamax	8/22/2016	Treatment of acute radiation syndrome	Neumedicines, Inc.
603	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogenic lung transplants	APT Pharmaceuticals, Inc.
604	propofol hemisuccinate	n/a	8/19/2016	Treatment of acute repetitive seizures	EpaleX Corporation
605	diazepam subcutaneous injection	Diazepen(Tm)	5/26/2016	Treatment of acute repetitive seizures.	Xeris Pharmaceuticals, Inc.
606	Perflubron	Liquivent(Tm)	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	PFC Development/New Alliance Pharmaceutical
607	calfactant	Infasurf	9/5/2000	Treatment of acute respiratory distress syndrome (ARDS)	ONY, Inc.
608	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Windtree Therapeutics, Inc.
609	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
610	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
611	(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
612	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
613	glyburide	n/a	9/29/2015	Treatment of acute spinal cord injury	Remedy Pharmaceuticals, Inc.
614	oligodendrocyte progenitor cells	n/a	2/2/2016	Treatment of acute spinal cord injury	Asterias Biotherapeutics
615	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
616	recombinant deriative of C3 transferase	Cethrin	11/18/2005	Treatment of acute spinal cord injury	Vertex Pharmaceuticals, Inc.
617	glyburide	n/a	2/8/2016	Treatment of acute subarachnoid hemorrhage	Remedy Pharmaceuticals, Inc.
618	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
619	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
620	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
621	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corporation
622	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
623	(monomethoxypolyethylene glycol) recombinant adenosine deaminase	n/a	3/19/2015	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	Sigma-Tau Pharmaceuticals, Inc.
624	autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 - based lentiviral vector, EFS-ADA	n/a	10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Donald B. Kohn, MD - Professor, UC-UCLA
625	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
626	hydrocortisone modified release capsules	Chronocort(R)	9/3/2015	Treatment of adrenal insufficiency.	Diurnal Ltd.
627	(N-[2,6-bis(1-methylethyl)-phey]-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.
628	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
629	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
630	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
631	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
632	brentuximab vedotin	n/a	5/23/2016	Treatment of adult T-cell leukemia/lymphoma	Seattle Genetics, Inc.
633	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Kirin Pharmaceutical Development, Inc.
634	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
635	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
636	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
637	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
638	Polyribonucleotide; Polyribo- inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS	Hemispherx Biopharma, Inc.
639	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
640	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
641	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
642	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
643	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
644	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
645	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
646	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
647	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM
648	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd
649	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
650	carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
651	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	n/a	10/15/2014	Treatment of AL Amyloidosis	ProteoTech, Inc.
652	recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
653	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Shire Human Genetic Therapies, Inc.
654	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
655	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
656	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
657	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
658	double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic	n/a	6/9/2015	Treatment of Alpha-1 Antitrypsin deficiency	Arrowhead Research Corporation
659	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
660	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
661	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Chiesi USA, Inc.
662	single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	n/a	7/17/2014	Treatment of Alport syndrome	Regulus Therapeutics, Inc.
663	flunarizine	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
664	flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
665	silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon(R) Sil	9/11/2014	Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure	Meda Pharmaceuticals, Inc.
666	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases
667	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases
668	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
669	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
670	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
671	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
672	autologous adipose derived mesenchymal stromal cells	n/a	10/22/2014	Treatment of amyotrophic lateral sclerosis	Mayo Clinic
673	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
674	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
675	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital
676	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
677	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Knopp Biosciences LLC
678	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
679	edaravone	n/a	3/12/2015	Treatment of amyotrophic lateral sclerosis	Treeway B.V.
680	edaravone	n/a	5/12/2015	Treatment of amyotrophic lateral sclerosis	Mitsubishi Tanabe Pharma Corporation
681	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
682	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
683	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
684	human glial restricted progenitor cells and their progeny	Q-Cells	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
685	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis	Neuralstem, Inc.
686	hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	n/a	3/9/2015	Treatment of amyotrophic lateral sclerosis	Alsonex Pty Ltd
687	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
688	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
689	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
690	Oxaloacetic acid	n/a	11/18/2015	Treatment of amyotrophic lateral sclerosis	Terra Biological LLC
691	recombinant human cerebral dopamine neurotrophic factor	n/a	6/8/2016	Treatment of amyotrophic lateral sclerosis	Herantis Pharma Plc
692	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
693	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
694	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
695	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
696	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
697	filgrastim	n/a	1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Neurovision Pharma GmbH
698	tirasemtiv	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
699	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
700	Mononuclear enriched fraction of human umbilical cord blood	U-Cord-Cell(R)	9/15/2015	Treatment of amyotrophic lateral sclerosis (ALS).	Saneron CCEL Therapeutics, Inc.
701	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab,LLC
702	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
703	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
704	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
705	masitinib mesylate	n/a	3/18/2015	Treatment of amyotrophic lateral sclerosis.	AB Science
706	noscaphine	n/a	12/29/2015	Treatment of amyotrophic lateral sclerosis.	KineMed Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
707	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
708	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
709	2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate	n/a	4/9/2015	Treatment of anal cancer	Eli Lilly and Company
710	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
711	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.
712	(1OR)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile	n/a	6/23/2015	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Pfizer, Inc.
713	brigatinib	n/a	4/28/2016	Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).	ARIAD Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
714	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	Mateon Therapeutics, Inc.
715	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
716	Cisplatin ChemoThin Wafer	n/a	11/3/2015	Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)	Privo Technologies
717	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
718	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
719	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
720	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
721	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Celgene Corporation
722	recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP	n/a	10/29/2015	Treatment of Angelman Syndrome.	Agilis Biotherapeutics, LLC
723	PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)	n/a	4/2/2015	Treatment of angiosarcoma	Co-D Therapeutics, Inc.
724	ataluren	n/a	9/1/2015	Treatment of aniridia	PTC Therapeutics, Inc.
725	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
726	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
727	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
728	antagonist of the complement 5a receptor	n/a	6/2/2014	Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.	ChemoCentryx, Inc.
729	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC
730	adult hemogenic endothelial cells	n/a	5/27/2015	Treatment of aplastic anemia	HemoGenyx LLC
731	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
732	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
733	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
734	pegylated human recombinant arginase I	n/a	3/16/2015	Treatment of arginase I deficiency (hyperargininemia).	AERase, Inc.
735	recombinant, adeno-associated virus serotype 2 vector carrying linear single-stranded AADC mRNA cDNA	n/a	6/8/2016	Treatment of aromatic L-amino acid decarboxylase deficiency.	Agilis Biotherapeutics, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
736	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of ascites due to all etiologies except for cancer	PharmaIN Corporation
737	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
738	ranagenglilotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
739	betamethasone	n/a	10/7/2015	Treatment of Ataxia Telangiectasia.	Grace Therapeutics, LLC
740	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
741	antagonist of the complement 5a receptor	n/a	11/17/2014	Treatment of atypical hemolytic uremic syndrome	ChemoCentryx, Inc.
742	recombinant human minibody against complement component	Mubodina(R)	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.A
743	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.
744	humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s (C1s)	n/a	7/27/2016	Treatment of autoimmune hemolytic anemia (AIHA)	True North Therapeutics, Inc.
745	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
746	naltrexone	n/a	1/13/2015	Treatment of autoimmune hepatitis	TaiwanJ Pharmaceuticals Co., Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
747	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
748	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.
749	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
750	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
751	Itraconazole	n/a	5/19/2016	Treatment of basal cell carcinoma nevus syndrome.	HedgePath Pharmaceuticals, Inc
752	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
753	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
754	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethynyl)-pyridin-2-yl]-benzonitrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
755	adalimumab	n/a	7/10/2014	Treatment of Behcet's disease	Mucora
756	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
757	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
758	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
759	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
760	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
761	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
762	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.
763	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
764	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
765	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
766	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
767	sirolimus	n/a	6/21/2016	Treatment of beta-thalassemia.	Rare Partners srl Impresa Sociale
768	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
769	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
770	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
771	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.
772	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
773	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumetica Pharmaceuticals A.G. (Schweiz)
774	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
775	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
776	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
777	humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/2014	Treatment of Bordetella pertussis	Synthetic Biologics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
778	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
779	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
780	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International Inc.
781	veliparib	n/a	12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	AbbVie Inc.
782	trans sodium crocetinate	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
783	[Î±-N-(2-succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[μ-N-(2-succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[μ-N-(2-succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	4/15/2015	Treatment of breast cancer patients with brain metastases	Angiochem, Inc.
784	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada Ltd.
785	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
786	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.
787	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.
788	erdosteine	n/a	12/20/2013	Treatment of bronchiectasis.	Alitair Pharmaceuticals, Inc.
789	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
790	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Windtree Therapeutics, Inc.
791	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
792	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
793	liposomal amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmed, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
794	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Celgene Corporation
795	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
796	autologous adipose tissue derived mesenchymal stem cells	n/a	5/4/2016	Treatment of Buerger's disease (thromboangiitis obliterans).	Biostar Stem Cell Research Institute
797	cultured skin substitute (CSS)	Novaderm	8/22/2016	Treatment of burns requiring skin grafting.	Regenicin Inc.
798	S3,S13-cyclo(D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide	n/a	11/16/2015	Treatment of C3 glomerulopathy.	Amyndas Pharmaceuticals
799	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
800	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
801	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
802	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
803	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
804	Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]	n/a	2/8/2016	Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.	Cidara Therapeutics, Inc.
805	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
806	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5]decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
807	Imiquimod	n/a	12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	UroGen Pharma Ltd
808	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
809	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
810	Vasomera	n/a	11/19/2015	Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and X-linked dilated cardiomyopathy (XL-dCMP).	PhaseBio Pharmaceuticals, Inc.
811	adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene	Calmarythm	10/2/2014	Treatment of catecholaminergic polymorphic ventricular tachycardia	Audentes Therapeutics, Inc.
812	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
813	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
814	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
815	Deslorelin	Somagard	11/5/1987	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
816	4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl	n/a	9/29/2015	Treatment of cerebral cavernous malformation.	REcursion Pharmaceuticals, LLC
817	Clazosentan	Erajel	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
818	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Baxalta US, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
819	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
820	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Retrophin, Inc.
821	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
822	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
823	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
824	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.
825	2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate	n/a	9/10/2015	Treatment of Charcot-Marie Tooth disease.	InFlectis BioScience
826	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SA
827	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
828	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
829	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	Teva Respiratory, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
830	sodium nitrite	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
831	6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole	n/a	5/11/2016	Treatment of cholangiocarcinoma	SynCore Biotechnology Co. Ltd.
832	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Concordia Laboratories, Inc.
833	(R)-6-(2-fluorophenyl)-N-(3-(2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride	n/a	11/19/2015	Treatment of cholangiocarcinoma.	ArQule, Inc.
834	gemcitabine	n/a	1/11/2016	Treatment of cholangiocarcinoma.	InnoPharmax, Inc.
835	melphalan	n/a	7/14/2015	Treatment of cholangiocarcinoma.	Delcath Systems, Inc.
836	Varlitinib	n/a	8/5/2015	Treatment of cholangiocarcinoma.	ASLAN Pharmaceuticals
837	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Alan L. Buchman, MD, MSPH
838	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/2014	Treatment of choroideremia	NightstaRx Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
839	aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Sparks Therapeutics, Inc.
840	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
841	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
842	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG
843	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Valeant Pharmaceuticals International, Inc.
844	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome	Hemispherx Biopharma, Inc.
845	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
846	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
847	ibrutinib	n/a	6/23/2016	Treatment of chronic Graft versus Host disease.	Pharmacyclics, LLC
848	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.
849	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Castle Creek Pharmaceuticals LLC
850	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
851	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
852	immune globulin infusion 10% (human) with recombinant human hyaluronidase)	n/a	3/31/2016	Treatment of chronic inflammatory demyelinating polyneuropathy	Baxalta US, Inc.
853	Immune Globulin Subcutaneous (Human), 20% Liquid	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	CSL Behring
854	recombinant multimerized human IgG1 Fc	n/a	7/14/2015	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
855	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thioxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
856	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
857	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
858	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
859	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
860	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
861	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
862	Bendamustine oral doseage formulation	n/a	11/5/2015	Treatment of chronic lymphocytic leukemia	Exinda Theapeutics LLC
863	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen, Inc.
864	cenersen	Aezea	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
865	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
866	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
867	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
868	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
869	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
870	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
871	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc.
872	phosphoinositide-3-kinase delta inhibitor	n/a	8/23/2016	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
873	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
874	ublrituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
875	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
876	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
877	rituximab and recombinant human hyaluronidase	Rituxin Sc	8/22/2016	Treatment of chronic lymphocytic leukemia (CLL)	Genentech, Inc.
878	Bruton's Tyrosine Kinase (Btk) Inhibitor	n/a	5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Acerta Pharma BV
879	mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37	n/a	3/24/2015	Treatment of chronic lymphocytic leukemia (CLL).	Boehringer Ingelheim Pharmaceuticals, Inc.
880	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.
881	duvelisib	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
882	(S)-7-(1acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide	n/a	7/20/2016	Treatment of chronic lymphocytic leukemia.	BeiGene USA, Inc.
883	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of chronic lymphocytic leukemia.	Kite Pharma, Inc.
884	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
885	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
886	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	Novartis Pharmaceuticals Corp.
887	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
888	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
889	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
890	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
891	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
892	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
893	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
894	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
895	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
896	tetrandrine	n/a	5/19/2016	Treatment of chronic myeloid leukemia.	Escend Pharmaceuticals, Inc.
897	purified autologous type 1 regulatory T lymphocytes specific for human type II collagen	n/a	9/1/2015	Treatment of chronic non-infectious uveitis	TxCell SA
898	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
899	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.
900	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
901	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
902	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
903	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
904	diphenylcyclopentenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
905	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
906	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
907	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
908	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
909	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
910	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Shire ViroPharma, Inc.
911	adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA	n/a	3/16/2016	Treatment of CLN2 disease (neuronal ceroid lipofuscinosis (NCL)) caused by TPP1 deficiency.	Spark Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
912	metronidazole	n/a	4/5/2016	Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).	Appili Therapeutics, Inc.
913	bevacizumab	n/a	3/10/2016	Treatment of Coat's disease	MicroSert, Ltd.
914	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)
915	selective inhibitor of fungal CYP51	n/a	3/3/2016	Treatment of coccidioidomycosis.	Viamet Pharmaceuticals, Inc.
916	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
917	hydromorphone hydrochloride (intrathecal infusion)	n/a	6/16/2016	Treatment of complex regional pain syndrome	Mallinckrodt Inc.
918	zoledronate D,L-lysine monohydrate (ZLM)	n/a	4/15/2015	Treatment of complex regional pain syndrome (CRPS)	Thar Pharmaceuticals
919	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
920	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
921	baclofen	Gablofen	10/28/2015	Treatment of complex regional pain syndrome.	Mallinckrodt, Inc.
922	hydrocortisone modified release capsules	Chronocort	3/18/2015	Treatment of congenital adrenal hyperpasia	Diurnal Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
923	2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-	n/a	1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Neurocrine Biosciences, Inc.
924	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
925	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
926	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
927	fully human IgG2 monoclonal antibody that binds insulin receptors	n/a	6/9/2015	Treatment of congenital hyperinsulinism	XOMA (US) LLC
928	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
929	trifarotene	n/a	6/6/2014	Treatment of congenital ichthyosis	Galderma R&D, LLC
930	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
931	4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one	n/a	5/4/2015	Treatment of congenital long QT syndrome	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
932	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited
933	amifampridine phosphate	n/a	3/3/2015	Treatment of congenital myasthenic syndromes	Catalyst Pharmaceuticals
934	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
935	autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.	n/a	6/30/2016	Treatment of congenital pseudarthrosis of the tibia	Novadip Biosciences
936	polidocanol	n/a	2/19/2015	Treatment of congenital venous malformations	Provensis Ltd
937	exendin-(9-39)	n/a	6/1/2011	Treatment of congenital hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	The Children's Hospital of Philadelphia
938	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
939	oral testosterone	n/a	6/2/2016	Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.	TesoRx Pharma, LLC
940	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
941	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
942	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
943	non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene	n/a	5/24/2016	Treatment of Crigler Najjar syndrome.	Audentes Therapeutics, Inc.
944	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
945	modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles	n/a	7/5/2016	Treatment of Crigler-Najjar syndrome	Alexion Pharmaceuticals, Inc.
946	adeno-associated viral vector expressing the human vascular endothelial growth factor gene	n/a	12/31/2015	Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated	Integene International Holding, LLC
947	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
948	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
949	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
950	selective inhibitor of fungal lanosterol demethylase	n/a	8/19/2014	Treatment of cryptococcal meningitis	Viamet Pharmaceuticals, Inc.
951	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
952	osilodrostat	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
953	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
954	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma
955	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
956	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
957	paromomycin	n/a	2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	The Surgeon General, Dept. of the Army

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
958	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
959	A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/2014	Treatment of cutaneous T-cell lymphoma	Angimmune, LLC
960	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
961	doxorubicin	n/a	4/6/2015	Treatment of cutaneous T-cell lymphoma	Louis D. Falo, Jr.
962	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
963	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	TetraLogic Pharmaceuticals
964	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
965	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	Soligenix, Inc.
966	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
967	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
968	afamelanotide	n/a	2/4/2016	Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease)	Clinuvel Inc.
969	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
970	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
971	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
972	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
973	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
974	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
975	S-nitrosoglutathione reductase inhibitor	n/a	1/13/2016	Treatment of cystic fibrosis	Nivalis Therapeutics, Inc.
976	(R)-1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
977	2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	n/a	5/13/2015	Treatment of cystic fibrosis	Flatley Discovery Lab
978	2-O-Butyryl-1-O-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

[illegible]

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
989	gentamicin C2 congener	n/a	3/29/2016	Treatment of cystic fibrosis	La Jolla Pharmaceuticals Company
990	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	Savara Inc.
991	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
992	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
993	leukotriene A4 hydrolase inhibitor	n/a	1/26/2015	Treatment of cystic fibrosis	Celtaxsys, Inc.
994	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
995	nitric oxide	n/a	9/23/2014	Treatment of cystic fibrosis	Advanced Inhalation Therapies Ltd.
996	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/2014	Treatment of cystic fibrosis	Imperial Innovations Limited
997	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
998	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
999	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
1000	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1001	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc
1002	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Askleion Pharmaceuticals, LLC
1003	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
1004	(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid	n/a	10/13/2015	Treatment of cystic fibrosis.	Corbus Pharmaceuticals, Inc.
1005	2-O-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1006	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
1007	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
1008	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
1009	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Windtree Therapeutics, Inc.
1010	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
1011	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.
1012	sodium alginate oligosaccharide	n/a	2/24/2016	Treatment of cystic fibrosis.	AlgiPharma AS

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1013	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1014	oxfendazole	n/a	7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Robert H. Gilman, MD, DTMH and
1015	Bucillamine	n/a	10/22/2015	Treatment of cystinuria	Revive Therapeutics, Ltd.
1016	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
1017	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
1018	liposomal glutathione	n/a	5/18/2016	Treatment of Dengue Virus infection.	Your Energy Systems, LLC
1019	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
1020	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
1021	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
1022	siponimod	n/a	7/10/2014	Treatment of dermatomyositis	Novartis Pharmaceuticals Corporation
1023	sodium thiosulfate	n/a	10/28/2014	Treatment of dermatomyositis	Hope Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1024	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
1025	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
1026	Recombinant coagulation factor VIIa	n/a	4/26/2006	Treatment of diffuse alveolar hemorrhage	Savara Inc.
1027	DNA plasmid vector expressing eIF5A κ 50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
1028	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
1029	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
1030	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.
1031	autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor	n/a	4/27/2016	Treatment of diffuse large B-cell lymphoma	Juno Therapeutics, Inc.
1032	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Denovo Biopharma LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1033	everolimus	n/a	6/2/2014	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corp.
1034	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, LLC
1035	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
1036	maytansinoid-conjugated humanized monoclonal antibody against CD37	n/a	5/12/2016	Treatment of diffuse large B-cell lymphoma	ImmunoGen, Inc.
1037	mocetinostat	n/a	8/7/2014	Treatment of diffuse large B-cell lymphoma	Mirati Therapeutics, Inc.
1038	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
1039	tisagenlecleucel-T	n/a	2/3/2015	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corporation
1040	C24H28N8O7S2	n/a	4/2/2015	Treatment of diffuse large B-cell lymphoma (DLBCL).	Curis, Inc.
1041	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie
1042	5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	n/a	3/31/2015	Treatment of diffuse large B-cell lymphoma.	Idera Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1043	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.
1044	daratumumab	Humax (R) - Cd38	11/9/2015	Treatment of diffuse large B-cell lymphoma.	Janssen Research and Development, LLC
1045	humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/2014	Treatment of diffuse large B-cell lymphoma.	MorphoSys AG
1046	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
1047	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
1048	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
1049	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Vericel Corporation.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1050	p38 mitogen-activated kinase inhibitor	n/a	5/27/2014	Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations	Array BioPharma, Inc.
1051	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer Inc.
1052	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
1053	cannabidiol	n/a	7/1/2014	Treatment of Dravet syndrome	Insys Therapeutics, Inc.
1054	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
1055	cannabidiol	n/a	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
1056	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
1057	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
1058	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzop[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
1059	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
1060	allogeneic cardiosphere-derived cells	n/a	4/21/2015	Treatment of Duchenne Muscular Dystrophy	Capricor, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1061	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
1062	bivalent anti-human myostatin adnectin-IgG1	n/a	2/10/2015	Treatment of duchenne muscular dystrophy	Bristol-Myers Squibb Co.
1063	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
1064	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
1065	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy	ReveraGen Biopharma
1066	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC
1067	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharaceuticals Limited
1068	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
1069	N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide	n/a	11/17/2014	Treatment of Duchenne muscular dystrophy	Catabasis Pharmaceuticals, Inc.
1070	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	Vudbenk Life Sciences
1071	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1072	recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter	n/a	6/16/2015	Treatment of Duchenne muscular dystrophy	Nationwide Children's Hospital
1073	recombinant human biglycan	n/a	7/13/2016	Treatment of Duchenne Muscular Dystrophy	Tivorsan Pharmaceuticals, Inc.
1074	tadalafil	Cialis(R); Adcirca(R)	5/4/2015	Treatment of Duchenne Muscular Dystrophy (DMD)	Eli Lilly and Company
1075	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
1076	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
1077	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.	BioMarin Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1078	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
1079	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	BioMarin Pharmaceutical, Inc.
1080	Exon 52 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	BioMarin Pharmaceutical, Inc.
1081	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	BioMarin Pharmaceutical, Inc.
1082	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	BioMarin Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1083	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
1084	Adeno-associated viral vector differentially expressing microdystrophin 5 gene via the muscle-specific promoter CK8.	n/a	8/31/2016	Treatment of Duchenne muscular dystrophy.	Solid GT, LLC
1085	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1086	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	BioMarin Pharmaceutical, Inc.
1087	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
1088	naproxcinod	n/a	3/16/2015	Treatment of Duchenne muscular dystrophy.	Nicox SA
1089	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
1090	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
1091	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
1092	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological
1093	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1094	autologous genetically modified human dermal fibroblasts	n/a	6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Fibrocell Technologies, Inc.
1095	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
1096	2-Ethylbutyl (2S)-2-[[[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate	n/a	9/18/2015	Treatment of Ebola virus disease	Gilead Sciences, Inc.
1097	aphidicolin	n/a	4/20/2016	Treatment of Ebola virus infection	Biospherics.net LLC
1098	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	n/a	8/25/2014	Treatment of Ebola virus infection	LeafBio, Inc.
1099	three human IgG1 mAbs (REGN3470, REGN3471, and REGN3479) directed against different epitopes on Ebola virus glycoprotein	n/a	7/14/2016	Treatment of ebola virus infection	Regeneron Pharmaceuticals, Inc.
1100	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	Celldex Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1101	celiprolol	n/a	1/5/2015	Treatment of Ehlers-Danlos syndrome	Acer Therapeutics, Inc.
1102	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
1103	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
1104	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
1105	single chain urokinase plasminogen activator	n/a	9/11/2014	Treatment of empyema (pleural)	Lung Therapeutics, Inc.
1106	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
1107	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
1108	brentuximab vedotin	Adcetris	7/7/2016	Treatment of enteropathy-associated T-cell lymphoma.	Seattle Genetics, Inc.
1109	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
1110	fluticasone propionate	n/a	12/29/2015	Treatment of eosinophilic esophagitis	Banner Life Sciences, LLC
1111	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1112	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/2015	Treatment of eosinophilic esophagitis	Receptos Services, LLC
1113	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
1114	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
1115	diacerein	n/a	10/15/2014	Treatment of epidermolysis bullosa	Castle Creek Pharmaceuticals
1116	dry extract from Betulae Cortex (birch bark)	n/a	8/7/2014	Treatment of epidermolysis bullosa	Birken AG
1117	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
1118	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck LLC
1119	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
1120	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1121	veliparib	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
1122	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
1123	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	FFCanVac Pte Ltd
1124	autologous Epstein-Barr virus specific T-cells	n/a	3/9/2015	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Cell Medica, Inc.
1125	allogeneic Epstein-Barr virus cytotoxic T lymphocytes	n/a	2/4/2016	Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders.	ATARA Biotherapeutics, Inc.
1126	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	Novartis Pharmaceuticals Corp.
1127	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	Novartis Pharmaceuticals Corp.
1128	vemurafenib	Zelboral	8/2/2016	Treatment of Erdheim-Chester Disease	Genentech, Inc.
1129	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
1130	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	Acorda Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1131	afamelanotide	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
1132	nivolumab	Opdivo	8/22/2016	Treatment of esophageal cancer	Bristol-Myers Squibb Co.
1133	paclitaxel aqueous gel	Oncogel(TM)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
1134	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
1135	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
1136	omeprazole-lansoprazole with buffer	n/a	2/10/2015	Treatment of esophageal ulcers	Effexus Pharmaceuticals, LLC
1137	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
1138	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
1139		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
1140	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of essential thrombocythemia	PharmaEssentia, Corporation
1141	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
1142	ANA-conjugated dactinomycin nanoemulsion	n/a	7/7/2015	Treatment of Ewing sarcoma	NanoSmart Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1143	Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor	n/a	6/30/2016	Treatment of Ewing sarcoma	Tokalas, Inc.
1144	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/2014	Treatment of Ewing's sarcoma	Gradalis, Inc.
1145	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
1146	phosphorothioate antisense oligonucleotide against EWS-Fli-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
1147	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
1148	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
1149	antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/2015	Treatment of Ewing's sarcoma.	NanoSmart Pharmaceuticals, Inc.
1150	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolipalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
1151	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1152	ublrituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
1153	lenalidomide	Revlimid	4/29/2015	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Celgene Corporation
1154	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclizethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
1155	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmed, Inc.
1156	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Faber disease	Enzyvant Sciences Ltd.
1157	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.
1158	lucerastat	n/a	10/29/2015	Treatment of Fabry Disease.	Actelion Pharmaceuticals Ltd
1159	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	8/26/2014	Treatment of Fabry's disease	Genzyme Corporation
1160	a-Galactosidase A	Plant-Produced Human A-Galactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
1161	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1162	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
1163	rapamycin	n/a	2/24/2016	Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).	DSLIP
1164	recombinant human histidyl tRNA synthetase	n/a	4/22/2015	Treatment of facioscapulohumeral muscular dystrophy	aTyr Pharma, Inc.
1165	pelareorep	Reolysin	2/24/2015	Treatment of fallopian tube cancer	Oncolytics Biotech, Inc.
1166	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
1167	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1168	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1169	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech
1170	pyrvinium	n/a	1/5/2015	Treatment of familial adenomatous polyposis	StemSynergy Therapeutics, Inc.
1171	magnesium lysinate bis eicosapentaenoate	n/a	12/23/2015	Treatment of familial adenomatous polyposis.	Thetis Pharmaceuticals
1172	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
1173	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1174	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.
1175	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
1176	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
1177	volanesorsen sodium, apolipoprotein C-III antisense oligonucleotide	n/a	6/23/2015	treatment of familial chylomicronemia syndrome	Ionis Pharmaceuticals, Inc.
1178	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
1179	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation
1180	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
1181	Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene	n/a	5/2/2016	Treatment of Fanconi anemia type A patients.	Centro de Investigacion Biomedica en Red (CIBER)
1182	triclabendazole	Triclatheara(Tm)	6/27/2016	Treatment of fascioliasis.	Tropicalis Pharmaceuticals, LLC
1183	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1184	triheptanoin	n/a	4/15/2015	Treatment of fatty acid oxidation disorders	Ultragenyx Pharmaceutical, Inc.
1185	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
1186	palovarotene	n/a	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Clementia Pharmaceuticals, Inc.
1187	3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
1188	3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)	n/a	7/14/2015	Treatment of fibrodysplasia ossificans progressiva.	La Jolla Pharmaceutical Company, Inc.
1189	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
1190	polyinosinic-polycytidilic acid	Poly-IcIc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
1191	sparsentan	n/a	1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Retrophin, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1192	propagermanium and irbesartan	n/a	12/9/2015	Treatment of focal segmental glomerulosclerosis.	Dimerix Bioscience Ltd.
1193	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
1194	¹⁷⁷ Lu-tetraxetan-tetulumab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
1195	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
1196	copanlisib	n/a	2/5/2015	Treatment of follicular lymphoma	Bayer HealthCare Pharmaceuticals, Inc.
1197	daratumumab	n/a	8/6/2015	Treatment of follicular lymphoma	Janssen Research & Development, LLC
1198	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
1199	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
1200	ibrutinib	n/a	9/8/2014	Treatment of follicular lymphoma	Pharmacyclics, LLC
1201	lenalidomide	Revlimid	9/17/2013	Treatment of follicular lymphoma	Celgene Corporation
1202	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
1203	rituximab and recombinant human hyaluronidase	n/a	8/22/2016	Treatment of follicular lymphoma	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1204	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/25/2016	Treatment of follicular lymphoma.	Kite Pharma, Inc.
1205	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
1206	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
1207	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1208	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
1209	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
1210	acetyl-L-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
1211	basimglurant	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1212	cannabidiol	n/a	2/23/2016	Treatment of Fragile X syndrome	Zynerba Pharmaceuticals, Inc.
1213	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
1214	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
1215	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.
1216	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
1217	(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	n/a	12/9/2015	Treatment of Fragile X Syndrome.	Centre National de la Recherche Scientifique (CNRS)
1218	bryostatin 1	n/a	3/31/2015	Treatment of Fragile X Syndrome.	Neurotrope BioScience, Inc.
1219	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
1220	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
1221	9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester	n/a	5/23/2016	Treatment of Friedreich's Ataxia	Retroitope, Inc.
1222	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia	ApoPharma, Inc.
1223	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi
1224	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1225	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
1226	interferon gamma-1b	Actimmune	10/1/2014	Treatment of Friedreich's Ataxia	Horizon Pharma Ireland Limited
1227	recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin	n/a	7/25/2016	Treatment of Friedreich's Ataxia	Agilis Biotherapeutics, LLC
1228	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison pharmaceuticals, Inc.
1229	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
1230	tolfenamic acid	n/a	7/13/2016	Treatment of Frontotemporal Dementia	Nasser H. Zawia
1231	cerebrolysin	n/a	4/5/2016	Treatment of frontotemporal dementia, including all subvariants	EVER Neuro Pharma GmbH
1232	1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one	n/a	4/6/2016	Treatment of frontotemporal dementia.	Anavex Life Sciences Corp.
1233	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
1234	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1235	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
1236	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
1237	miconazole	n/a	5/22/2014	Treatment of fungal otitis externa (otomycosis)	Hill Dermaceuticals, Inc.
1238	clotrimazole otic solution	n/a	5/10/2016	Treatment of fungal otitis externa (otomycosis).	Laboratorios SALVAT S.A.
1239	antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/2014	Treatment of gastric cancer	Millennium Pharmaceuticals, Inc.
1240	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	NeoviiBiotech North America, Inc.
1241	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
1242	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1243	eflornithine HCL	n/a	4/7/2015	Treatment of gastric cancer	Cancer Prevention Pharmaceuticals, Inc.
1244	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer	Cancer Advances, Inc.
1245	liposome encapsulated paclitaxel	n/a	12/3/2014	Treatment of gastric cancer	Insys Therapeutics, Inc.
1246	pelareorep	Reolysin	5/4/2015	Treatment of gastric cancer	Oncolytics Biotech, Inc.
1247	recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4	n/a	7/16/2015	Treatment of gastric cancer	Gilead Sciences, Inc.
1248	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
1249	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
1250	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
1251	masitinib mesylate	n/a	9/14/2015	Treatment of gastric cancer including cancer of the gastroesophageal junction	AB Science
1252	recombinant, glycoengineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b	n/a	6/29/2016	Treatment of gastric cancer including cancer of the gastroesophageal junction.	Five Prime Therapeutics, Inc.
1253	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
1254	napabucasin	n/a	6/20/2016	Treatment of gastric cancer including gastroesophageal junction cancer.	Boston Biomedical, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1255	pembrolizumab	Keytruda	6/16/2015	Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma	Merck, Sharp & Dohme
1256	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer, including gastroesophageal junction cancer	Genentech, Inc.
1257	C21H27O10P	Minnelide	3/30/2015	Treatment of gastric cancer.	Minneamrita Therapeutics, LLC
1258	varlitinib	n/a	6/20/2016	Treatment of gastric cancer.	ASLAN Pharmaceuticals
1259	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepine-3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
1260	(R)-1-[1-(4-Acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea	n/a	5/12/2016	Treatment of gastric neuroendocrine tumors (gastric NETs).	Trio Medicines Ltd.
1261	lutetium (177Lu)-edotreotide	n/a	5/21/2015	Treatment of gastro-entero-pancreatic neuroendocrine tumors	ITG Isotope Technologies Garching GmbH
1262	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Advanced Accelerator Applications
1263	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1264	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
1265	Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Deciphera Pharmaceuticals, LLC
1266	ponatinib	Iclusig(R)	3/12/2015	Treatment of gastrointestinal stromal tumors (GIST).	ARIAD Pharmaceuticals, Inc.
1267	Small Molecule Inhibitor of Exon 17 mutant KIT	n/a	1/6/2016	Treatment of gastrointestinal stromal tumors (GIST).	Blueprint Medicines Corporation
1268	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic graft versus host disease in patients undergoing allogeneic hematopoietic cell transplantation	Soligenix, Inc.
1269	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	n/a	9/11/2014	Treatment of Gaucher disease	Genzyme
1270	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	Belrose Pharma, Inc.
1271	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
1272	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1273	solnatide	n/a	2/8/2016	Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)	Apeptico Forschung und Entwicklung GmbH
1274	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
1275	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
1276	3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione	n/a	3/29/2016	Treatment of glioblastoma	Actuate Therapeutics
1277	Anti-Beta1 integrin monoclonal antibody	n/a	8/7/2014	Treatment of glioblastoma	OncoSynergy, Inc.
1278	autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line	n/a	5/6/2015	Treatment of glioblastoma	Sebastiano Gattoni-Celli, MD
1279	cediranib	n/a	12/13/2010	Treatment of glioblastoma	National Institutes of Health
1280	nivolumab	n/a	8/27/2015	Treatment of glioblastoma	Bristol-Myers Squibb Co
1281	trans sodium crocetinate	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1282	olaptosed pegol	n/a	8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Noxxon Pharma AG
1283	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/2015	Treatment of glioblastoma multiforme	Diffusion Pharmaceuticals, Inc.
1284	aldoxorubicin	n/a	9/24/2014	Treatment of glioblastoma multiforme	CytRx Corporation
1285	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2'-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
1286	cannabidiol	n/a	8/20/2014	Treatment of glioblastoma multiforme	Insys Therapeutics, Inc.
1287	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Denovo Biopharma LLC
1288	Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/2014	Treatment of glioblastoma multiforme	AbbVie, Inc.
1289	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	CTI BioPharma Corporation
1290	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1291	saposin C	n/a	2/3/2015	Treatment of glioblastoma multiforme	Bexion Pharmaceuticals, LLC
1292	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.
1293	[AC3-gCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
1294	nano-diamino-tetraiodothyroacetic acid	n/a	7/9/2015	Treatment of glioblastoma multiforme (GBM)	NanoPharmaceuticals, LLC
1295	6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide	n/a	2/11/2016	Treatment of glioblastoma multiforme (GBM).	Upsher-Smith Laboratories, Inc.
1296	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
1297	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1298	2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}{2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of glioblastoma multiforme.	Rgenix, Inc.
1299	altiratinib	n/a	8/19/2014	Treatment of glioblastoma multiforme.	Deciphera Pharmaceuticals, LLC
1300	chloroquine	n/a	5/20/2015	Treatment of glioblastoma multiforme.	DualTpharma B.,V.
1301	combination of disulfiram and copper gluconate	n/a	5/18/2016	Treatment of glioblastoma multiforme.	Cantex Pharmaceuticals, Inc.
1302	Disufenton sodium	n/a	8/22/2016	Treatment of glioblastoma multiforme.	Oblato, Inc.
1303	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
1304	human recombinant bone morphogenetic protein 4	n/a	5/4/2016	Treatment of glioblastoma multiforme.	HyperStem Therapeutics, Inc.
1305	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.
1306	methimazole and liothyronine sodium	n/a	6/2/2016	Treatment of glioblastoma multiforme.	Musli Thyropeutics Ltd
1307	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Cavion, LLC
1308	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexix, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1309	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2, TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
1310	7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl	n/a	6/23/2016	Treatment of glioblastoma.	Oncocutics, Inc.
1311	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
1312	(S)-perillyl alcohol temozolomide	n/a	11/12/2014	Treatment of glioma	NeOnc Technologies, Inc.
1313	adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma	n/a	10/1/2014	Treatment of glioma	DNAtrix, Inc.
1314	Azurin-p28	n/a	12/2/2015	Treatment of glioma	CDG Therapeutics, Inc.
1315	cannabidiol	n/a	9/24/2014	Treatment of glioma	Insys Therapeutics, Inc.
1316	fosbretabulin tromethamine	n/a	6/8/2016	Treatment of glioma	Mateon Therapeutics, Inc.
1317	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
1318	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1319	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
1320	perillyl alcohol	n/a	4/18/2011	Treatment of glioma	NeOnc Technologies, Inc.
1321	pritumumab	n/a	10/28/2014	Treatment of glioma	Nascent Biotech, Inc.
1322	recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2	n/a	5/26/2016	Treatment of glioma	Darell D. Bigner, MD, PhD
1323	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
1324	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
1325	delta-9-tetrahydrocannabinol and cannabidiol	n/a	12/3/2015	Treatment of glioma.	GW Research Ltd.
1326	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
1327	human leukocyte antigen-A2 restricted peptides	n/a	1/26/2015	Treatment of glioma.	Stemline Therapeutics, Inc.
1328	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.
1329	N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine	n/a	2/18/2016	Treatment of glioma.	Flag Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1330	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences
1331	antineoplaston A10, antineoplaston AS2-1	n/a	11/21/2008	Treatment of gliomas	Burzynski Research Institute, Inc.
1332	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
1333	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
1334	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.
1335	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
1336	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
1337	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
1338	triheptanoin	n/a	10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Ultragenyx Pharmaceutical, Inc.
1339	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
1340	amylpectin	n/a	3/24/2015	Treatment of glycogen storage disease types Ia and Ib	Michael K. Davis, MD, MBA
1341	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
1342	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1343	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
1344	alpha-1 proteinase inhibitor (human)	Glassia	10/23/2014	Treatment of graft versus host disease	Kamada Ltd.
1345	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
1346	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
1347	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.A.
1348	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
1349	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited
1350	recombinant human deoxyribonuclease I	n/a	8/18/2014	Treatment of graft-vs-host disease	SciVac Ltd.
1351	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
1352	growth hormone releasing hormone, 1-44 human amide	n/a	2/23/2016	Treatment of growth hormone deficiency	Hollenbeck Pharmaceuticals, Inc.
1353	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency	OPKO Biologics Ltd.
1354	recombinant human serum albumin human growth hormone	n/a	1/13/2016	Treatment of growth hormone deficiency	TEVA Branded Pharmaceutical Products R&D, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1355	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
1356	Recombinant protein inhibitor of complement factor 5	n/a	5/10/2016	Treatment of Guillain-Barre Syndrome.	Akari Therapeutics Plc
1357	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
1358	vemurafenib	Zelboraf	8/26/2014	Treatment of hairy cell leukemia (HCL).	Genentech, Inc.
1359	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
1360	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
1361	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1362	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.
1363	flunarizine	n/a	7/20/2016	Treatment of hemiplegic migraine	Xenon Pharmaceuticals, Inc.
1364	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.
1365	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Genentech

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1366	immunologically active synthetic peptides	n/a	6/1/2015	Treatment of Hemophilia A	Apitope International NV
1367	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
1368	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
1369	human monoclonal antibody directed against tissue factor pathway inhibitor	n/a	5/18/2016	Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients.	Pfizer, Inc.
1370	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
1371	adeno-associated virus vector encoding the SQ variant of human blood clotting factor VIII	n/a	2/29/2016	Treatment of Hemophilia A.	BioMarin Pharmaceutical, Inc.
1372	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadfviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation
1373	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Baxalta US, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1374	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.
1375	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
1376	adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX	n/a	9/21/2015	Treatment of hemophilia B.	Spark Therapeutics, Inc.
1377	Adeno-associated virus serotype rh10 vector encoding the human factor IX gene	n/a	8/25/2015	Treatment of hemophilia B.	Dimension Therapeutics
1378	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
1379	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International
1380	Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide	n/a	3/31/2015	Treatment of hepatitis D virus infection.	MYR GmbH

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1381	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
1382	small molecule FGFR4 inhibitor	n/a	9/14/2015	Treatment of hepatocellular cancer (HCC).	Blueprint Medicines Corporation
1383	(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminoxy)propionyl]- 1H-pyrano[3',4',6',7',]indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
1384	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/2014	Treatment of hepatocellular carcinoma	CASI Pharmaceuticals, Inc.
1385	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
1386	antroquinonol	n/a	7/23/2015	Treatment of hepatocellular carcinoma	Golden Biotechnology Corporation
1387	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1388	everolimus	Afinitor	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1389	hepcortespenlisimut-L	n/a	12/17/2014	Treatment of hepatocellular carcinoma	Immunitor, Inc.
1390	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
1391	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
1392	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
1393	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
1394	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
1395	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	SillaJen Biotherapeutics, Inc.
1396	propranolol hydrochloride and etodolac	n/a	2/24/2015	Treatment of hepatocellular carcinoma	Vicus Therapeutics, LLC
1397	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
1398	ramucirumab	n/a	11/4/2011	Treatment of hepatocellular carcinoma	Eli Lilly and Company
1399	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
1400	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation
1401	tirapazamine	n/a	11/30/2015	Treatment of hepatocellular carcinoma	Teclison Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1402	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company
1403	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
1404	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.
1405	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
1406	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
1407	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.
1408	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1409	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1410	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
1411	nivolumab	Opdivo(R)	9/2/2015	Treatment of hepatocellular carcinoma.	Bristol-Myers Squibb Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1412	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Mondobiotech Laboratories AG
1413	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
1414	regorafenib	Stivarga	6/4/2015	Treatment of hepatocellular carcinoma.	Bayer HealthCare Pharmaceuticals, Inc.
1415	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.
1416	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development
1417	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
1418	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
1419	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
1420	human monoclonal antibody directed against active plasma kallikrein	n/a	11/26/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
1421	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
1422	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1423	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
1424	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
1425	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	Escala Therapeutics, Inc.
1426	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.
1427	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
1428	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
1429	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Santen SAS
1430	acyclovir	n/a	5/3/2016	Treatment of herpetic keratitis.	Cumulus Pharmaceuticals LLC
1431	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/16/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH
1432	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
1433	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1434	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute
1435	ibalizumab	n/a	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	TaiMed Biologics, Inc.
1436	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
1437	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.
1438	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
1439	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
1440	(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	n/a	4/29/2015	Treatment of Hodgkin lymphoma	Incyte Corporation
1441	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1442	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed GmbH
1443	pembrolizumab	Keytruda	12/30/2015	Treatment of Hodgkin lymphoma.	Merck, Sharp & Dohme Corp.
1444	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of Hodgkin lymphoma.	Gamida Cell Ltd.
1445	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
1446	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	Alissa Pharma, LLC
1447	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	Mirati Therapeutics, Inc.
1448	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
1449	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1450	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1451	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.
1452	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	n/a	3/17/2015	Treatment of homocystinuria	Orphan Technologies Limited
1453	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
1454	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
1455	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Gemphire Therapeutics, Inc.
1456	2-[4-[[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	3/18/2015	Treatment of homozygous familial hypercholesterolemia (HoFH)	CymaBay Therapeutics, Inc.
1457	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
1458	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1459	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
1460	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
1461	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Amarantus BioScience Holdings, Inc.
1462	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
1463	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
1464	fexinidazole	n/a	4/4/2016	Treatment of human African trypanosomiasis (HAT) or sleeping sickness	Sanofi US Services, Inc.
1465	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
1466	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1467	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1468	Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)	n/a	9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Etubics Corporation
1469	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
1470	5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride	n/a	9/4/2014	Treatment of Huntington's disease	Prana Biotechnology Limited
1471	Antisense oligonucleotide targeted to the huntingtin protein	n/a	12/29/2015	Treatment of Huntington's disease	Isis Pharmaceuticals, Inc.
1472	carbenoxolone	n/a	7/2/2014	Treatment of Huntington's Disease	Oxalys Pharmaceuticals, Inc.
1473	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
1474	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
1475	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Marathon Pharmaceuticals, LLC
1476	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1477	d6-tetrabenazine, deutetabenazine	n/a	11/5/2014	Treatment of Huntington's Disease	Teva Pharmaceuticals, Inc.
1478	humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen	n/a	8/16/2016	Treatment of Huntington's disease	Vaccinex, Inc.
1479	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
1480	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation
1481	ubiquinol	Ubi-Q-Nol, Li-Q-Nol	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp.
1482	antisense oligonucleotide targeting the U isoform of SNP rs362307	n/a	6/16/2016	Treatment of Huntington's disease (prodromal stage Huntington's disease and diagnosed Huntington's disease)	Wave Life Sciences
1483	2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-methyl]-quinoline succinic acid	n/a	6/2/2014	Treatment of Huntington's disease.	Pfizer Inc.
1484	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
1485	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1486	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
1487	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1488	phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethylethyl) monohydrochloride	n/a	3/16/2015	Treatment of Huntington's disease.	Ipsen Biopharmaceuticals, Inc.
1489	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1490	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1491	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.
1492	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1493	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1494	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
1495	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
1496	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
1497	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.
1498	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
1499	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
1500	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
1501	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
1502	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1503	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome	Novartis Pharmaceuticals Corporation
1504	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC
1505	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1506	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1507	non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/2014	Treatment of hypoparathyroidism	Chugai Pharma USA, LLC
1508	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.
1509	recombinant human alkaline phosphatase	n/a	5/13/2015	Treatment of hypophosphatasia.	AM-Pharma BV
1510	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1511	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD
1512	xenon gas	n/a	12/3/2014	Treatment of hypoxic ischemic encephalopathy	Neuroprotexon
1513	phenobarbitol sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates	Fera Pharmaceuticals, LLC
1514	pentetrazol	n/a	9/9/2015	Treatment of idiopathic hypersomnia.	Balance Therapeutics, Inc.
1515	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
1516	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.
1517	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomeasure, Inc.
1518	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1519	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
1520	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
1521	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
1522	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
1523	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
1524	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
1525	lebrikizumab	n/a	3/9/2015	Treatment of idiopathic pulmonary fibrosis	Genentech, Inc.
1526	pirfenidone	n/a	7/31/2014	Treatment of idiopathic pulmonary fibrosis	Genoa Pharmaceuticals, Inc.
1527	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
1528	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
1529	tetra-substituted porphyrin derivative containing manganese (III)	n/a	3/16/2015	Treatment of idiopathic pulmonary fibrosis	Aeolus Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1530	tipelukast	n/a	10/20/2014	Treatment of idiopathic pulmonary fibrosis	MediciNova, Inc.
1531	carbon monoxide	n/a	8/16/2016	Treatment of idiopathic pulmonary fibrosis (IPF).	Proterris, Inc.
1532	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
1533	3-pentylbenzenacetic acid sodium salt	n/a	2/11/2015	Treatment of idiopathic pulmonary fibrosis.	ProMetic Life Sciences, Inc.
1534	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
1535	monoclonal antibody targeting eotaxin-2	n/a	10/29/2015	Treatment of idiopathic pulmonary fibrosis.	ChemomAb, Ltd.
1536	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
1537	1-(3-chloro-5-{{4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl}carbonyl}-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
1538	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	PhytoHealth Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1539	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
1540	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS
1541	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
1542	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1543	fostamatinib disodium	n/a	8/25/2015	Treatment of immune thrombocytopenic purpura	Rigel Pharmaceuticals, INC.
1544	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
1545	staphylococcal aureus protein A	n/a	6/10/2015	Treatment of immune thrombocytopenic purpura	Protalex, Inc.
1546	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
1547	Recombinant humanized monoclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
1548	veltuzumab	n/a	7/28/2015	Treatment of immune thrombocytopenic purpura.	Immunomedics, Inc.
1549	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1550	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.
1551	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.
1552	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.
1553	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
1554	blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen, Inc.
1555	N-t-butylhydroxylamine	n/a	5/12/2015	Treatment of infantile neuronal ceroid lipofuscinosis.	Andrew Lim
1556	cannabidiol	n/a	7/23/2015	Treatment of infantile spasms	Insys Therapeutics, Inc.
1557	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1558	tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride	n/a	6/20/2016	Treatment of infantile spasms	Anavex Life Sciences Corp.
1559	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceuticals, Inc.
1560	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
1561	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
1562	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	n/a	11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Khondrion BV
1563	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
1564	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1565	Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1566	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
1567	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
1568	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1569	pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/2015	Treatment of intracerebral hemorrhage	CereNOva, LLC
1570	recombinant activated Factor X variant	n/a	3/3/2015	Treatment of intracerebral hemorrhage	Pfizer, Inc.
1571	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
1572	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Theraeputics, Inc.
1573	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Metacel Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1574	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
1575	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
1576	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD
1577	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
1578	Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-}. Al(III)	n/a	12/29/2015	Treatment of invasive aspergillosis.	Vical Incorporated
1579	(1,3)-β-D-glucan synthesis inhibitor	n/a	8/22/2016	Treatment of invasive Aspergillus infections	SCYNEXIS, Inc.
1580	enfumafungin derivative B-(1,3)-D-glucan synthetis inhibitor	n/a	5/10/2016	Treatment of invasive Candida infections, including candidemia	SCYNEXIS, Inc.
1581	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.
1582	isavuconazonium sulfate	n/a	10/20/2014	Treatment of invasive candidiasis/candidemia	Astellas Pharma Global Development, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1583	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
1584	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
1585	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1586	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
1587	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
1588	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
1589	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
1590	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.
1591	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
1592	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
1593	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1594	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1595	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
1596	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.
1597	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
1598	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
1599	ibudilast	n/a	6/1/2015	Treatment of Krabbe disease	MediciNova, Inc.
1600	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
1601	Angiotensin (1-7)	n/a	2/8/2016	Treatment of LAMA2-related muscular dystrophy	Tarix Orphan, LLC
1602	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation
1603	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
1604	amifampridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceuticals, Inc.
1605	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
1606	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1607	NorLeu3-Angiotensin(1-7)) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
1608	adenovirus associated viral vector serotype 5 containing the human RPE65 gene	n/a	3/10/2016	Treatment of Leber congenital amaurosis	MeiraGTx Limited
1609	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, Inc.
1610	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
1611	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
1612	antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA	n/a	5/25/2016	Treatment of Leber's congenital amaurosis.	ProQR Therapeutics IV B.V.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1613	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation
1614	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
1615	vatiquinone	Vincerinone	6/4/2014	Treatment of Leigh Syndrome	Edison Pharmaceuticals, Inc.
1616	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv
1617	cannabidiol	n/a	6/23/2014	Treatment of Lennox-Gastaut syndrome	Insys Therapeutics, Inc.
1618	cannabidiol;	n/a	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.
1619	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
1620	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Aegerion Pharmaceuticals, Inc.
1621	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
1622	Amantadine HCl	n/a	7/20/2015	Treatment of levodopa-induced dyskinesia	Osmotica Pharmaceutical Corporation
1623	Amantadine hydrochloride	Nurelin	4/9/2015	Treatment of levodopa-induced dyskinesia	Adamas Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1624	eltoprazine HCl	n/a	2/8/2016	Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.	Amarantus BioScience Holdings, Inc.
1625	dipraglurant	n/a	12/29/2015	Treatment of levodopa-induced dyskinesias	Addex Pharma SA
1626	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
1627	sotalol hydrochloride	Sotylize	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
1628	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
1629	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
1630	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
1631	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
1632	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1633	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
1634	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.
1635	ceramide	n/a	8/8/2016	Treatment of liver cancer	Keystone Nano, Inc.
1636	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
1637	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1638	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1639	HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex	n/a	4/19/2016	Treatment of localized scleroderma.	Fibrocell Technologies, Inc.
1640	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
1641	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.
1642	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1643	sirolimus	n/a	6/25/2014	Treatment of lymphangioleiomyomatosis	LAM Therapeutics, Inc.
1644	sirolimus	n/a	11/17/2011	Treatment of lymphangioleiomyomatosis	Cote Orphan Consulting, LLC
1645	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
1646	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.
1647	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Gilead Sciences, Inc.
1648	dusquetide	n/a	8/10/2016	Treatment of macrophage activation syndrome	Soligenix, Inc.
1649	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
1650	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
1651	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1652	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
1653	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1654	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1655	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
1656	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
1657	cis-adamantane-2-spiro-3'-8'-[4'-(2'-(4'-morpholinyl)ethoxy)phenyl]-1',2',4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
1658	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium falciparum	Zydus Pharmaceuticals, Inc.
1659	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
1660	N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine	n/a	10/29/2015	Treatment of malaria.	Donald J. Krogstad, MD
1661	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1662	afatinib	Gilotrif(R)	6/4/2014	Treatment of malignant brain and central nervous system tumors	Boehringer Ingelheim Pharmaceuticals, Inc.
1663	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
1664	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
1665	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
1666	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
1667	butylidenephthalide	n/a	8/5/2015	Treatment of Malignant Glioma	Everfront Biotech, Inc.
1668	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
1669	crenolanib besylate	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
1670	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	Aettis, Inc.
1671	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
1672	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1673	pelareorep	Reolysin	4/15/2015	Treatment of malignant glioma	Oncolytics Biotech, Inc.
1674	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1675	procaspase-activating compound 1	n/a	7/23/2015	Treatment of malignant glioma	Vanquish Oncology, Inc.
1676	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Oncotelic Inc.
1677	dabrafenib	Tafinlar	2/8/2016	Treatment of malignant glioma with BRAF V600 mutation	Novartis Pharmaceuticals Corporation
1678	Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex	n/a	7/23/2015	Treatment of malignant glioma.	Ziopharm Oncology, Inc.
1679	marizomib	n/a	9/21/2015	Treatment of malignant glioma.	Triphase Research & Development I Corp.
1680	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
1681	propranolol and etodolac	n/a	7/8/2015	Treatment of malignant glioma.	Vicus Therapeutics, LLC
1682	1,2:5,6-Dianhydrogalactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	DelMar Pharmaceuticals, Inc.
1683	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1684	Diphenylcyclopropenone gel	Samcyprone (Tm)	4/15/2015	Treatment of malignant melanoma stage IIB to IV	RXi Pharmaceuticals Corp.
1685	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.
1686	tumor-infiltrating lymphocytes; LN-144	n/a	6/9/2015	Treatment of malignant melanoma Stages IIb to IV	Lion Biotechnologies, Inc.
1687	2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/23/2015	Treatment of malignant melanoma stages IIB to IV.	Rgenix, Inc.
1688	Endothelin receptor B antagonist	n/a	1/21/2016	Treatment of malignant melanoma Stages IIB to IV.	ENB Therapeutics, LLC
1689	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV
1690	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/2014	Treatment of malignant mesothelioma	Oncos Therapeutics
1691	profimer sodium	Photofrin(R)	12/2/2011	Treatment of malignant mesothelioma	Concordia Laboratories, Inc.
1692	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1693	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
1694	tremelimumab	n/a	3/18/2015	Treatment of malignant mesothelioma	MedImmune, LLC
1695	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.
1696	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
1697	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
1698	tazemetostat	n/a	2/4/2016	Treatment of malignant rhabdoid tumors (MRTs)	Epizyme Inc.
1699	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
1700	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
1701	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
1702	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
1703	triterpenoid saponin	n/a	7/23/2014	Treatment of mantle cell lymphoma	Avicin Therapeutics, Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1704	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazine-1-yl)-N-(pyridine-2-yl)-benzamide	n/a	9/21/2015	Treatment of mantle cell lymphoma.	Acerta Pharma BV
1705	(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydroprazolo[1,5-a]pyrimidine-3-carboxamide	n/a	6/23/2016	Treatment of mantle cell lymphoma.	BeiGene USA, Inc.
1706	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/28/2016	Treatment of mantle cell lymphoma.	Kite Pharma, Inc.
1707	daratumumab	n/a	8/20/2015	Treatment of mantle cell lymphoma.	Janssen Research & Development, LLC
1708	sodium phenylbutyrate	n/a	8/19/2014	Treatment of maple syrup urine disease	Acer Therapeutics, Inc.
1709	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
1710	ketotifen	n/a	2/25/2015	Treatment of mastocytosis	Valcrest Pharmaceuticals, LLC
1711	masitinib	n/a	9/14/2005	Treatment of mastocytosis	AB Science
1712	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
1713	small molecule inhibitor of Exon 17 Mutant KIT	n/a	1/21/2016	Treatment of mastocytosis	Blueprint Medicines Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1714	cromolyn sodium for inhalation	n/a	12/9/2015	Treatment of mastocytosis.	Patara Pharma, LLC
1715	sonidegib	n/a	3/23/2015	Treatment of medulloblastoma	Novartis Pharmaceuticals Corp.
1716	1,2:5,6-dianhydrogalactitol	n/a	3/10/2016	Treatment of medulloblastoma.	DelMar Pharmaceuticals, Inc.
1717	levomefolate calcium	n/a	2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Cox Biosciences LLC
1718	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
1719	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
1720	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
1721	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
1722	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
1723	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
1724	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1725	recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1)	n/a	9/21/2015	Treatment of merkel cell carcinoma.	EMD Serono, Inc.
1726	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
1727	adenovirus vaccine encoding reduced expression in immortalized cell protein	n/a	7/14/2015	Treatment of mesothelioma	MTG Biotherapeutics
1728	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
1729	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
1730	bevacizumab	Avastin	1/27/2016	Treatment of mesothelioma	Genentech, Inc.
1731	N-methyl-4-({4-[(3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
1732	Human wilms tumor protein 1 peptides	n/a	2/23/2016	treatment of mesothelioma.	SELLAS Life Sciences Group
1733	Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	Not Determined	3/24/2015	Treatment of mesothelioma.	Aduro BioTech, Inc.
1734	pegargiminase	n/a	7/21/2014	Treatment of mesothelioma.	Polaris Group

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1735	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
1736	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
1737	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
1738	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
1739	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.
1740	Rose Bengal Disodium	n/a	12/21/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
1741	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
1742	[131I]-N-(2-(diethylamino) ethyl-4-(4 fluorebenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)
1743	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
1744	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
1745	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1746	Interleukin-2	Teceleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
1747	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
1748	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
1749	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
1750	uridine triacetate	n/a	9/3/2009	Treatment of mitochondrial disease	Wellstat Therapeutics Corporation
1751	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
1752	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc.
1753	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
1754	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1755	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
1756	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy	Heart Metabolics, Limited.
1757	cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion (R)	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
1758	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
1759	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.
1760	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.
1761	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
1762	pentosan polysulfate sodium	Lysosan (Tm)	1/5/2015	Treatment of mucopolysaccharidosis (MPS) type VI	Plexcera Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1763	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/2014	Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)	BioMarin Pharmaceutical, Inc.
1764	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Alexion Pharmaceuticals, Inc.
1765	IDUA-HIRMAb fusion protein	n/a	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
1766	ataluren	Translarna	12/10/2014	Treatment of mucopolysaccharidosis type I	PTC Therapeutics, Inc.
1767	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
1768	aden-associated virus vector serotype 9 expressing human alpha-L-iduronidase	n/a	9/29/2015	Treatment of mucopolysaccharidosis Type I (MSP I).	REGENXBIO, Inc.
1769	non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase	n/a	12/8/2015	Treatment of Mucopolysaccharidosis Type II	REGENXBIO, Inc.
1770	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1771	adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene	n/a	7/16/2015	Treatment of mucopolysaccharidosis type II (Hunter syndrome).	Laboratorios del Dr. Esteve, S.A.
1772	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
1773	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
1774	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
1775	adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH)	n/a	11/18/2015	Treatment of mucopolysaccharidosis type IIIA or Sanfilippo type A syndrome	LYSOGENE
1776	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.
1777	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1778	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
1779	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
1780	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
1781	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.
1782	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-One	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB
1783	1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	n/a	12/3/2014	Treatment of multiple myeloma	Cellectar Biosciences, Inc.
1784	1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide	n/a	7/8/2015	Treatment of multiple myeloma	Cleave Biosciences, Inc.
1785	6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine	n/a	6/12/2014	Treatment of multiple myeloma	DARA BioSciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1786	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
1787	autologous T-lymphocytes transduced with anti-BCMA02 CAR lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human B cell maturation antigen	n/a	5/11/2016	Treatment of multiple myeloma	bluebird bio, Inc.
1788	avicin d	n/a	3/24/2015	Treatment of multiple myeloma	Avicin Therapeutics Ltd.
1789	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1790	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation
1791	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
1792	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, LLC
1793	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
1794	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
1795	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1796	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.
1797	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
1798	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.
1799	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
1800	oprozomib	n/a	10/28/2014	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
1801	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
1802	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
1803	ronaparstat	n/a	3/19/2015	Treatment of multiple myeloma	Sigma-Tau Research Switzerland S.A.
1804	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
1805	selinexor	n/a	1/5/2015	Treatment of multiple myeloma	Karyopharm Therapeutics, Inc.
1806	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1807	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
1808	Venetoclax	n/a	8/29/2016	Treatment of multiple myeloma	AbbVie Inc.
1809	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
1810	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.
1811	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
1812	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
1813	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
1814	DNA plasmid vector expressing eIF5A κ 50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
1815	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.
1816	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi U.S. Services, Inc.
1817	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
1818	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1819	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
1820	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1821	pembrolizumab	Keytruda	2/17/2016	Treatment of multiple myeloma.	Merck, Sharp & Dohme Corp.
1822	synthetic signal peptide of human mucin-1 (amino acids 1-21)	n/a	6/16/2015	Treatment of multiple myeloma.	Vaxil Bio Therapeutics Ltd.
1823	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
1824	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrophin gene	PTC Therapeutics, Inc.
1825	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutiple myeloma	XTL Biopharmaceuticals, Ltd
1826	Methotrexate	Amethopterin	8/28/2014	Treatment of Myasthenia Gravis	The Universtiy of Kanasa Medical Center
1827	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1828	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
1829	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
1830	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Alpha Cancer Technologies, Inc.
1831	tolerogen	n/a	2/5/2015	Treatment of myasthenia gravis	Toleranzia AB
1832	eculizumab	n/a	6/12/2014	Treatment of Myasthenia Gravis.	Alexion Pharmaceuticals, Inc.
1833	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
1834	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
1835	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
1836	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
1837	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
1838	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1839	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
1840	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1841	humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2)	n/a	8/30/2016	Treatment of myelodysplastic syndrome	Opsona Therapeutics Ltd.
1842	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A.DE C.V.
1843	imetelstat	n/a	12/23/2015	Treatment of myelodysplastic syndrome	Janssen Research & Development, LLC
1844	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
1845	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
1846	Mocetinostat	n/a	6/12/2014	Treatment of myelodysplastic syndrome	Mirati Therapeutics, Inc.
1847	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH
1848	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Celgene Corporation
1849	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1850	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
1851	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
1852	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
1853	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of myelodysplastic syndrome.	Gamida Cell Ltd.
1854	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
1855	rigosertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
1856	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
1857	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Clinigen Group plc
1858	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
1859	R11 retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
1860	imetelstat	n/a	6/11/2015	Treatment of myelofibrosis	Janssen Research & Development, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1861	N-(cyanomethyl)-4-(2-([4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
1862	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
1863	recombinant human Pentraxin-2	n/a	8/26/2014	Treatment of myelofibrosis	Promedior, Inc.
1864	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
1865	mecasermin	lplex	12/3/2007	Treatment of myotonic dystrophy	Insmed, Inc.
1866	synthetic oligomer of 16 nucleotides	n/a	1/13/2015	Treatment of myotonic dystrophy Type I	Ionis Pharmaceuticals, Inc.
1867	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
1868	mazindol	n/a	7/6/2016	Treatment of narcolepsy	NLS-0 Pharma AG
1869	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
1870	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
1871	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1872	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	La Jolla Pharmaceutical Company, Inc.
1873	arimoclomol citrate	n/a	1/13/2015	Treatment of Neimann-Pick disease, type C	Orphazyme ApS
1874	glibentek (glibenclamide oral suspension)	n/a	6/8/2016	Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy)	AMMTeK
1875	N-Methanocarbathymidine	n/a	10/15/2014	Treatment of neonatal herpes	N & N Pharmaceuticals, Inc.
1876	cannabidiol	n/a	4/22/2015	Treatment of neonatal hypoxic ischemic encephalopathy	GW Pharma Ltd.
1877	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
1878	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
1879	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1880	Mafofosamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1881	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
1882	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.
1883	6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one	n/a	6/18/2015	Treatment of Netherton syndrome	Sixera Pharma AB
1884	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
1885	131-I-8H9 monoclonal antibody	n/a	8/29/2016	Treatment of neuroblastoma	Memorial Sloan Kettering Cancer Center
1886	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer, Inc.
1887	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
1888	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1889	entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	12/22/2014	Treatment of neuroblastoma	Ignyta, Inc.
1890	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
1891	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1892	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
1893	MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin	n/a	9/23/2014	Treatment of Neuroblastoma	MabVax Therapeutics, Inc.
1894	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
1895	anisina	n/a	7/14/2015	Treatment of neuroblastoma.	Novogen Ltd
1896	firtecan pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
1897	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
1898	sodium 2-hydroxylinoleate	n/a	8/25/2015	Treatment of neuroblastoma.	Ability Pharmaceuticals, SL
1899	90Y-DOTA-tyr3-Octreotide	n/a	1/20/2016	Treatment of neuroendocrine tumors	M. Sue O'Dorisio, MD, PhD
1900	fosbretabulin tromethamine	n/a	12/29/2015	Treatment of neuroendocrine tumors	Mateon Therapeutics, Inc.
1901	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
1902	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1903	lobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
1904	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
1905	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1906	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
1907	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
1908	bortezomib	n/a	7/5/2016	Treatment of neurofibromatosis type 2 (NF2)	BioXcel Corporation
1909	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
1910	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
1911	cladribine	n/a	3/19/2015	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chord Therapeutics S.a.r.l.
1912	humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chugai Pharma USA, LLC
1913	ublituximab	n/a	8/25/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	TG Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1914	humanized affinity-optimized, afucosylated immunoglobulin G1 kappa monoclonal antibody against CD19	n/a	2/10/2016	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders	MedImmune, LLC
1915	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
1916	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.
1917	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
1918	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
1919	recombinant human nerve growth factor	n/a	6/23/2014	Treatment of neurotrophic keratitis	Dompe s.p.a.
1920	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
1921	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute
1922	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
1923	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Sphingo Biotech, LLC
1924	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann Pick disease, type C.	Vtesse, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1925	ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Pharmacyclics, LLC
1926	ublrituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
1927	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
1928	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
1929	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.
1930	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
1931	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
1932	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1933	sodium ascorbate and menadione sodium bisulfite	Apatone	4/9/2015	Treatment of noninfected painful total joint without mechanical complication	IC-MedTech Corporation
1934	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1935	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
1936	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
1937	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
1938	rociletinib	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.
1939	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)
1940	dacomitinib	n/a	3/3/2015	Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.	Pfizer, Inc.
1941	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
1942	enochleated amikacin	n/a	3/3/2016	Treatment of non-tuberculous mycobacteria (NTM) infections	Aquarius Biotechnologies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1943	2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide	n/a	9/29/2015	Treatment of nuclear protein in testis (NUT) midline carcinoma.	Genentech, Inc (a Roche Group Member)
1944	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
1945	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
1946	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BioBlast Pharma, Ltd.
1947	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
1948	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1949	methotrexate oral solution	n/a	8/27/2015	Treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age	Silvergate Pharmaceuticals, Inc.
1950	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by <i>Onchocerca volvulus</i>	Janssen Research & Development, LLC
1951	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis <i>volvulus</i> in children and adults.	Medicines Development Limited
1952	N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxopyrrolidin-1-yl)propyl]-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/2014	Treatment of optic neuritis	Bionure Farma SL
1953	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1954	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation
1955	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
1956	Sucalfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.
1957	carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Orphan Europe SARL
1958	recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase	n/a	12/29/2015	Treatment of ornithine transcarbamylase deficiency	Dimension Therapeutics
1959	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
1960	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
1961	human allogeneic bone marrow derived osteoblastic cells	n/a	11/9/2015	Treatment of osteogenesis imperfecta.	Bone Therapeutics SA
1962	human monoclonal antibody targeting human sclerostin	n/a	2/29/2016	Treatment of osteogenesis imperfecta.	Mereo Biopharma 3 Limited
1963	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1964	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
1965	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.
1966	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
1967	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
1968	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals LLC
1969	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
1970	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center
1971	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
1972	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolidpalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1973	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.
1974	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
1975	(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxamide	n/a	4/14/2016	Treatment of ovarian cancer	DebioPharm International SA
1976	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
1977	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics
1978	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
1979	aldoxorubicin	n/a	9/24/2014	Treatment of ovarian cancer	CytRx Corporation
1980	anlotinib hydrochloride	n/a	12/31/2015	Treatment of ovarian cancer	Advenchen Laboratories, LLC
1981	anti-Beta1 integrin monoclonal antibody	n/a	1/13/2015	Treatment of ovarian cancer	OncoSynergy, Inc.
1982	anti-HER2 bispecific antibody	n/a	5/18/2016	Treatment of ovarian cancer	Zymeworks Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1983	anti-HER2 bispecific antibody drug conjugate	n/a	7/6/2016	Treatment of ovarian cancer	Zymeworks Inc.
1984	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
1985	binimetinib	n/a	7/31/2014	Treatment of ovarian cancer	Array Biopharma, Inc.
1986	cantrixil	n/a	4/20/2015	Treatment of ovarian cancer	CanTx, Inc.
1987	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	Neoviibiotech North America, Inc.
1988	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
1989	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	Mateon Therapeutics, Inc.
1990	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
1991	defactinib	n/a	2/12/2015	Treatment of ovarian cancer	Verastem, Inc.
1992	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	SimRx Advisors LLC
1993	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
1994	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.
1995	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of ovarian cancer	Sun Pharmaceutical Industries Ltd.
1996	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1997	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech
1998	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals LLC
1999	liposomal encapsulated paclitaxel	n/a	1/21/2015	Treatment of ovarian cancer	Insys Therapeutics, Inc.
2000	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	PharmaMar USA, Inc.
2001	maytansinoid conjugated humanized monoclonal antibody against FOLRI	n/a	7/14/2014	Treatment of ovarian cancer	ImmunoGen, Inc.
2002	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Cavion, LLC
2003	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl}oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/2014	Treatment of ovarian cancer	Amgen, Inc.
2004	nanoparticulate paclitaxel	Nanotax	10/6/2015	Treatment of ovarian cancer	NanOlogy, LLC
2005	niraparib	n/a	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
2006	oglufanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2007	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2008	pelareorep	Reolysin(R)	2/10/2015	Treatment of ovarian cancer	Oncolytics Biotech, Inc.
2009	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2010	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2011	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
2012	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2013	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2014	small molecule normalizing the p53 function	n/a	6/12/2014	Treatment of ovarian cancer	Critical Outcome Technologies, Inc.
2015	Sperm Protein-17 oral microparticle vaccine	n/a	6/21/2016	Treatment of ovarian cancer	Kiromic, LLC
2016	thioureidobutyronitrile	Kevetrin	7/14/2015	Treatment of ovarian cancer	Cellceutix Corporation
2017	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
2018	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Endocyte, Inc.
2019	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3 H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
2020	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2021	1,2:5,6-dianhydrogalactitol	n/a	4/19/2016	Treatment of ovarian cancer.	DelMar Pharmaceuticals, Inc. (Clinical Operations)
2022	2-{3-[(3R)-3-([2-chloro-3-(trifluoromethyl)phenyl)methyl](2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid	n/a	6/16/2015	Treatment of ovarian cancer.	Rgenix, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2023	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
2024	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.
2025	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
2026	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Celsion Corporation
2027	DPX-Survivac	n/a	7/14/2015	Treatment of ovarian cancer.	Immunovaccine Technologies, Inc.
2028	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics
2029	human soluble receptor-Fc fusion protein that targets human activin A	n/a	10/14/2015	Treatment of ovarian cancer.	Atara Biotherapeutics
2030	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation
2031	mifepristone	Korlym	1/14/2016	Treatment of ovarian cancer.	Corcept Therapeutics, Inc.
2032	multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200)	n/a	12/7/2015	Treatment of ovarian cancer.	Tapimmune, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2033	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
2034	Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.	n/a	5/23/2016	Treatment of ovarian cancer.	PeptiMed
2035	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
2036	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Novartis Pharmaceuticals Corp.
2037	poly-CD-PEG-camptothecin	n/a	5/21/2015	Treatment of ovarian cancer.	Cerulean Pharma, Inc.
2038	Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH	n/a	2/4/2016	Treatment of ovarian cancer.	Soricimed Biopharma Inc.
2039	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
2040	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
2041	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2042	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2043	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2044	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
2045	bupivacaine hydrochloride	n/a	5/31/2016	treatment of pain associated with postherpetic neuralgia.	Grace Therapeutics, LLC
2046	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
2047	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.
2048	mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Relmada Therapeutics, Inc.
2049	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
2050	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc.
2051	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
2052	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2053	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Oncos Therapeutics
2054	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate	n/a	1/26/2015	Treatment of pancreatic cancer	Incyte Corporation
2055	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
2056	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC
2057	5,5',5"-[Phosphinothiolydine-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
2058	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.
2059	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2060	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
2061	anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody	n/a	8/29/2016	Treatment of pancreatic cancer	Singh Biotechnology, LLC
2062	antroquinonol	n/a	1/21/2015	Treatment of pancreatic cancer	Golden Biotechnology Corp.
2063	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
2064	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.
2065	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
2066	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	Ganymed Pharmaceuticals AG
2067	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
2068	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKtor Pharmaceuticals, LLC
2069	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2070	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
2071	double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/2015	Treatment of pancreatic cancer	Silenseed Ltd
2072	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
2073	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
2074	gemcitabine ready-to-use	n/a	6/24/2015	Treatment of pancreatic cancer	Sun Pharmaceutical Industries Ltd.
2075	heat killed whole cell mycobacterium obuense	n/a	9/23/2014	Treatment of pancreatic cancer	Immodulon Therapeutics Limited
2076	heparan sulfate mimetic	n/a	5/29/2014	Treatment of pancreatic cancer	Momenta Pharmaceuticals, Inc.
2077	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/2014	Treatment of pancreatic cancer	Karcinolys S.A.S.
2078	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2079	human trivalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)	n/a	10/22/2014	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
2080	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
2081	LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL	n/a	5/4/2015	Treatment of pancreatic cancer	Lokon Pharma AB
2082	metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide	n/a	7/6/2016	Treatment of pancreatic cancer	Avenzoar Pharmaceuticals, Inc.
2083	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
2084	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2085	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
2086	N1,N14,-diethyl-3,12,-dihydroxyhomospermine	n/a	8/7/2014	Treatment of pancreatic cancer	Sun BioPharma, Inc.
2087	nano-diamino-tetraiodothyroacetic acid	n/a	10/28/2015	Treatment of pancreatic cancer	NanoPharmaceuticals, LLC
2088	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
2089	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	SynCore Biotechnology Co., Ltd.
2090	paclitaxel nanoparticles	n/a	1/2/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2091	PEGylated recombinant human hyaluronidase PH20	n/a	10/1/2014	Treatment of pancreatic cancer	Halozyme Therapeutics, Inc.
2092	Pegylated recombinant human interleukin-10	n/a	7/18/2016	Treatment of pancreatic cancer	ARMO BioSciences, Inc.
2093	pelareorep	Reolysin(R)	2/11/2015	Treatment of pancreatic cancer	Oncolytics Biotech, Inc.
2094	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2095	S-[2,3-bisphalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDENISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
2096	tarextumab	n/a	1/26/2015	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2097	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd
2098	[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone	n/a	10/20/2014	Treatment of pancreatic cancer	Synovo GmbH
2099	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.
2100	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Nuvilex, Inc.
2101	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one	n/a	9/23/2014	Treatment of pancreatic cancer.	Rexahn Pharmaceuticals, Inc.
2102	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation
2103	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
2104	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
2105	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
2106	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
2107	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2108	ganitumab	n/a	11/23/2010	Treatment of pancreatic cancer.	Nantcell
2109	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
2110	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
2111	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
2112	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
2113	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Cavion, LLC
2114	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
2115	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/2014	Treatment of pancreatic cancer.	Millennium Pharmaceuticals, Inc.
2116	nimotuzumab	n/a	9/8/2015	Treatment of pancreatic cancer.	InnoCIMab Pte Ltd
2117	Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH	n/a	6/29/2016	Treatment of pancreatic cancer.	Soricimed Biopharma, Inc.
2118	pritumumab	n/a	4/6/2016	Treatment of pancreatic cancer.	Nascent Biotech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2119	propranolol and etodolac	n/a	4/27/2015	Treatment of pancreatic cancer.	Vicus Therapeutics, LLC
2120	Re188 P2045 somatostatin peptide analogue	n/a	6/19/2014	Treatment of pancreatic cancer.	Andarix Pharmaceuticals, Inc.
2121	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.
2122	rigosertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2123	sacituzumab govitecan	n/a	5/29/2014	Treatment of pancreatic cancer.	Immunomedics, Inc.
2124	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2125	taurolidine	n/a	5/16/2016	Treatment of pancreatic cancer.	Geistlich Pharma NA, Inc.
2126	thioureidobutyronitrile	Kevetrin	1/20/2016	Treatment of pancreatic cancer.	Cellceutix Corporation
2127	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Oncotelic, Inc.
2128	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
2129	pantothenate phosphate	n/a	5/4/2015	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Retrophin, Inc.
2130	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2131	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition associated liver disease	Fresenius Kabi Deutschland GmbH
2132	Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Apellis Pharmaceuticals, Inc.
2133	S3,S13-cyclo(D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	n/a	10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Amyndas Pharmaceuticals
2134	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	CURx Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2135	anti-TCR murine monoclonal antibody (MAb, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.
2136	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Allergan, Inc.
2137	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia
2138	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
2139	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2140	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
2141	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl]carbamoyl}carbo nylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
2142	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
2143	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
2144	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	Seattle Genetics, Inc.
2145	Tesevatinib	n/a	3/1/2016	Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD)	Kadmon Corporation, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2146	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrottemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2147	dabrafenib	Tafinler	10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Novartis Pharmaceuticals Corp
2148	dabrafenib and trametinib	n/a	10/29/2015	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Novartis Pharmaceuticals Corp.
2149	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/2014	Treatment of patients with carbon monoxide poisoning	University of Pittsburgh
2150	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
2151	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
2152	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG
2153	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
2154	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Kirin Pharmaceutical Development Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2155	human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI)	n/a	11/3/2015	Treatment of patients with cystic fibrosis.	Shire
2156	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
2157	4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate	n/a	11/18/2015	Treatment of patients with Duchenne Muscular Dystrophy.	ARMGO Pharma, Inc.
2158	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
2159	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis	Shire ViroPharma Incorporated
2160	ibrutinib	Imbruvica	2/2/2016	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Pharmacyclics, LLC
2161	2-[4-[[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	4/15/2015	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	CymaBay Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2162	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
2163	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
2164	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
2165	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
2166	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
2167	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2168	pentetate trisodium	Diethylenetriaminepentaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2169	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
2170	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2171	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	ReGenTree, LLC
2172	vemurafenib	Zelboraf	9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600E mutation	Genentech, Inc.
2173	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
2174	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
2175	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
2176	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2177	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
2178	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.
2179	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2180	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.
2181	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
2182	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Alliance Pharmaceuticals Ltd
2183	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
2184	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation
2185	chromium picolinate and chromium histidinate	n/a	12/22/2014	Treatment of pediatric polycystic ovary syndrome (0 through 16 years of age)	JDS Therapeutics, LLC
2186	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2187	deflazacort	n/a	10/22/2015	Treatment of pediatric (0 through 16 years of age) juvenile idiopathic arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.	Marathon Pharmaceuticals, LLC
2188	ozanimod	n/a	12/29/2015	Treatment of pediatric (0 through 16 years of age) ulcerative colitis	Receptos Services, LLC
2189	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
2190	(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate	n/a	9/18/2015	Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA	AbbVie, Inc.
2191	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2192	hydrocortisone oral granules	Infacort(R)	5/13/2015	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Diurnal Limited
2193	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Adare Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2194	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
2195	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
2196	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of Tishcon Corporation
2197	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
2198	mongersen	n/a	7/20/2015	Treatment of pediatric Crohn's disease	Celgene Corporation
2199	ustekinumab	Stelara	5/18/2016	Treatment of pediatric Crohn's disease (0 through 16 years of age)	Janssen Research & Development, LLC
2200	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
2201	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
2202	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
2203	Bacillus subtilis oxalate decarboxylase	n/a	2/29/2016	Treatment of pediatric hyperoxaluria	Allena Pharmaceuticals
2204	paricalcitol	Zemplar	10/27/2015	Treatment of pediatric hyperparathyroidism	Abbvie, inc.
2205	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2206	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.
2207	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2208	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
2209	modified a-cobratoxin	n/a	9/1/2015	Treatment of pediatric multiple sclerosis (0 through 16 years of age).	Nutra Pharma Corporation
2210	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.
2211	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences
2212	ivabradine	n/a	3/23/2016	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Amgen, Inc.,
2213	human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interleukin-17A	n/a	2/4/2016	Treatment of pediatric patients 0 to	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2214	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2215	Ombitasvir/Paritaprevir/Ritonavir	Technivie® Tablets	2/24/2016	Treatment of pediatric patients with chronic hepatitis C virus infection	AbbVie Inc.
2216	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
2217	ombitasvir/paritaprevir/ritonavir and dasabuvir	Viekira Pak	7/16/2015	Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age)	Abbvie, Inc.
2218	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
2219	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.
2220	guanfacine and amphetamine	n/a	3/17/2016	Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age)	Genco Sciences, LLC
2221	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
2222	etrolizumab	n/a	8/22/2016	Treatment of pediatric patients with ulcerative colitis	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2223	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
2224	metformin	n/a	5/29/2014	Treatment of pediatric polycystic ovary syndrome	EffRx Pharmaceuticals SA
2225	benzoate	Naben	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
2226	cannabidiol	n/a	11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Insys Therapeutics, Inc.
2227	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
2228	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
2229	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
2230	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Avaxia Biologics, Incorporated
2231	veltuzumab	n/a	11/17/2014	Treatment of pemphigus	Immunomedics, Inc.
2232	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	n/a	1/26/2015	Treatment of pemphigus vulgaris	Almirall S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2233	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
2234	rituximab	Rituxan(R); Mabthera(R)	2/23/2015	Treatment of pemphigus vulgaris.	Genentech, Inc.
2235	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
2236	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
2237	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.
2238	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd
2239	chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells	n/a	7/28/2016	Treatment of peripheral T-cell lymphoma	iCell Gene Therapeutics
2240	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
2241	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.
2242	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
2243	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Solasia Pharma K.K.
2244	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Kirin Pharmaceutical Development, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2245	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
2246	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.
2247	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.
2248	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2249	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
2250	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC
2251	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell transfusion dependent.	Celgene Corporation
2252	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2253	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{{(3S)-3-(dimethylamino)pyrrolidin-1-yl)methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
2254	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
2255	recombinant humanized IgG4 monoclonal antibody that binds human colony stimulating factor 1 receptor	n/a	1/11/2016	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Five Prime Therapeutics, Inc.
2256	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.
2257	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/2014	Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath	Novartis Pharmaceuticals Corp

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2258	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Daiichi Sankyo, Inc.
2259	melphalan flufenamide hydrochloride	n/a	3/16/2015	Treatment of plasma cell myeloma, also referred to as multiple myeloma	Oncopeptides AB
2260	rt-PA	Activase	10/20/2014	Treatment of plastic bronchitis	Kathleen A Stringer, PharmD, FCCP - Professor
2261	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
2262	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.
2263	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
2264	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited
2265	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
2266	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2267	golimumab	Simponi Aria	4/2/2015	Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.	Janssen Research & Development, LLC
2268	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.
2269	N-tert-butyl-3-[(5-methyl-2-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
2270	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2271	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2272	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
2273	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
2274	stemchymal	n/a	12/16/2015	Treatment of polyglutamine spinocerebellar ataxia	Steminent Biotherapeutics, Inc.
2275	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Audentes Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2276	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
2277	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2278	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2279	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
2280	amitriptyline and ketamine	Amiket(Tm)	1/19/2010	Treatment of postherpetic neuralgia	Immune Pharmaceuticals, Inc.
2281	d-methadone	n/a	6/2/2016	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
2282	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
2283	naltrexone	n/a	2/23/2015	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2284	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC
2285	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
2286	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
2287	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2288	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
2289	Human immune globulin	Flebogamma(R) 5% Dif	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
2290	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
2291	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Avivia Project BV
2292	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited
2293	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
2294	carbetocin (nasal spray)	n/a	4/11/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
2295	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
2296	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
2297	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.
2298	oxytocin	n/a	11/24/2014	Treatment of Prader-Willi syndrome	Pr Maithe Tauber
2299	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
2300	setmelanotide	n/a	9/21/2015	Treatment of Prader-Willi Syndrome.	Rhythm Metabolics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2301	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi USA, Inc.
2302	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
2303	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
2304	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Shire Human Genetic Therapies, Inc.
2305	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
2306	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
2307	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2308	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
2309	Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
2310	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir
2311	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
2312	solnatide	n/a	2/4/2016	Treatment of primary graft dysfunction following lung transplantation	Apeptico Forschung und Entwicklung GmbH
2313	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
2314	synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	n/a	4/22/2015	Treatment of primary hyperoxaluria type 1	Dicerna Pharmaceuticals, Inc.
2315	synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA	n/a	2/8/2016	Treatment of primary hyperoxaluria type 1	Alnylam Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2316	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2317	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
2318	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
2319	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
2320	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
2321	pembrolizumab	Ketruda	1/14/2016	Treatment of primary mediastinal B cell lymphoma.	Merck, Sharp & Dohme Corp.
2322	autologous T-cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor	n/a	4/20/2016	Treatment of primary mediastinal B-cell lymphoma.	Kite Pharma, Inc.
2323	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.A.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2324	pacritinib	n/a	3/13/2008	Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF	CTI BioPharma Corporation
2325	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
2326	pelareorep	Reolysin(R)	2/24/2015	Treatment of primary peritoneal cancer	Oncolytics Biotech, Inc.
2327	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Shire Human Genetic Therapies, Inc.
2328	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
2329	docosahexaenoic acid, DHA	n/a	12/17/2014	Treatment of primary sclerosing cholangitis	Sancilio and Company, Inc.
2330	simtuzumab	n/a	1/5/2015	Treatment of primary sclerosing cholangitis	Gilead Sciences, Inc.
2331	9,10-dimethoxy-5,6-dihydro-[1	n/a	8/29/2016	Treatment of primary sclerosing cholangitis.	HighTide Biopharma Pty. Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2332	recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)	n/a	8/25/2016	Treatment of primary sclerosing cholangitis.	Biotie Therapies Corp.
2333	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	Teva Pharmaceuticals USA
2334	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
2335	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Shire Human Genetic Therapies, Inc.
2336	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestasis	Albireo AB

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2337	imatinib mesylate	n/a	5/6/2014	Treatment of progressive multifocal leukencephalopathy	Inhibikase Therapeutics, Inc.
2338	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
2339	(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane	n/a	6/23/2014	Treatment of progressive supranuclear palsy	Cortice Biosciences, Inc.
2340	Anti-eTau Humanized IgG4 Monoclonal Antibody	n/a	5/13/2015	Treatment of Progressive Supranuclear Palsy	Britol-Myers Squibb Company
2341	recombinant humanized anti-tau antibody	n/a	1/22/2015	Treatment of progressive supranuclear palsy	AbbVie, Inc.
2342	tolfenamic acid	n/a	7/13/2016	Treatment of progressive supranuclear palsy	Nasser H. Zawia
2343	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
2344	competetive small molecule inhibitor of the enzyme O-GlcNAcase	n/a	3/10/2016	Treatment of progressive supranuclear palsy.	Merck & Company, Inc.
2345	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2346	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen, Inc.
2347	setmelanotide	n/a	4/4/2016	Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene	Rhythm Pharmaceuticals, Inc.
2348	3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cypyrudin-2-amine bis-mesylate	n/a	11/9/2015	Treatment of Proteus Syndrome.	ArQule, Inc.
2349	ganaxolone	n/a	3/24/2015	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Marinus Pharmaceuticals, Inc.
2350	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
2351	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University
2352	(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)	n/a	4/21/2016	Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients	Neem Biotech Ltd.
2353	sodium nitrite and EDTA	n/a	11/10/2015	Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis	Arch Biopartners, Inc.
2354	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Savara Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2355	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
2356	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)carbamooyl)-5-methylpyridin-1-ium	n/a	11/17/2014	Treatment of pulmonary arterial hypertension	Pulmokine, Inc.
2357	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
2358	2-[[[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoxy)methyl)cyclohexyl)methoxy] acetic acid	n/a	8/28/2014	Treatment of pulmonary arterial hypertension	Arena Pharmaceuticals, Inc.
2359	ambrisentan/tadalafil fixed combination	n/a	8/22/2016	Treatment of pulmonary arterial hypertension	Gilead Sciences, Inc.
2360	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
2361	bardoxolone	n/a	3/30/2015	Treatment of pulmonary arterial hypertension	Reata Pharmaceuticals, Inc.
2362	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
2363	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
2364	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinova Pharma GmbH
2365	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2366	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Airess Pharmaceuticals, Inc.
2367	tacrolimus	n/a	5/4/2015	Treatment of pulmonary arterial hypertension	Stanford University School of Medicine
2368	tiprelestat	Elafin	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG
2369	treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump	n/a	12/29/2015	Treatment of pulmonary arterial hypertension	SteadyMed Therapeutics
2370	(S)-8-{2-Amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester	n/a	10/6/2015	Treatment of pulmonary arterial hypertension (PAH).	KAROS Pharmaceuticals, Inc.
2371	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
2372	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.
2373	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2374	tacrolimus	n/a	3/16/2015	Treatment of pulmonary arterial hypertension.	Selten Pharma, Inc.
2375	ubenimex	n/a	11/19/2015	Treatment of pulmonary arterial hypertension.	Eiger BioPharmaceuticals, Inc.
2376	itraconazole inhalation powder	n/a	8/16/2016	Treatment of pulmonary fungal infections in patients with cystic fibrosis	Pulmatrix, Inc
2377	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	CURx Pharmaceuticals, Inc.
2378	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2379	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Forest Research Institute, Inc.
2380	poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine	n/a	4/5/2016	Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa, Burkholderia cepacia and other bacteria	TGV-Inhalonix, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2381	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)pipe- ridin-1-yl]phenoxy-methyl}-2,3- dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd
2382	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
2383	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
2384	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
2385	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
2386	allosteric activator of the red blood cell-specific form of pyruvate kinase	n/a	3/24/2015	Treatment of pyruvate kinase deficiency	Agios Pharmaceuticals, Inc.
2387	lentiviral vector containing the human liver and erythroid pyruvate kinase gene	n/a	3/23/2016	Treatment of pyruvate kinase deficiency.	Centro de Investigacion Biomedica en RED (CIBER)
2388	PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCA TT 3'	lmt504	11/24/2014	Treatment of rabies virus infections	Mid-Atlantic BioTherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2389	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
2390	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2391	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.
2392	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
2393	encapsulated spores from fecal microbiota	n/a	8/19/2015	Treatment of recurrent Clostridium difficile infection (CDI)	Seres Health, Inc.
2394	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2395	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
2396	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
2397	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
2398	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
2399	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.
2400	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
2401	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
2402	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
2403	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
2404	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2405	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated
2406	Girentuximab	Rencarex	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
2407	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
2408	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Horizon Pharma Ireland Limited
2409	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
2410	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
2411	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
2412	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
2413	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Windtree Therapeutics, Inc.
2414	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.
2415	mesencephalic, astrocyte-derived neurotrophic factor	n/a	9/10/2015	Treatment of retinal artery occlusion.	Amarantus BioScience Holdings, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2416	His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2	n/a	1/13/2016	Treatment of retinal detachment	ONL Therapeutics, Inc
2417	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, Inc
2418	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
2419	4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide	n/a	2/8/2016	Treatment of retinitis pigmentosa	Shire HGT, Inc.
2420	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
2421	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
2422	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
2423	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2424	human recombinant mesencephalic, astrocyte derived neurotrophic factor	n/a	12/22/2014	Treatment of retinitis pigmentosa	Amarantus BioScience Holdings, Inc.
2425	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
2426	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
2427	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/2014	Treatment of retinitis pigmentosa	RetroSense Therapeutics, LLC
2428	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2429	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2430	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2431	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	R-Tech Ueno, Ltd.
2432	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc
2433	Lentiviral vector containing the human MYO7A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2434	adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	n/a	3/18/2015	Treatment of Retinitis Pigmentosa due to autosomal recessive RPE65 gene mutations	Spark Therapeutics, Inc.
2435	adenovirus-associated viral vector serotype 5 containing the human pde6B gene	n/a	7/5/2016	Treatment of retinitis pigmentosa due to pde6B gene mutations	HORAMA, SAS
2436	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
2437	thioureidobutyronitrile	Kevetrin	11/17/2015	Treatment of retinoblastoma.	Cellceutix Corporation
2438	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[5-methylpyrimidin-2-ylmethyl)amino)methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolaxis, Inc.
2439	acetyl-L-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	Sigma-Tau Pharmaceuticals, Inc.
2440	glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/2015	Treatment of Rett syndrome	Neuren Pharmaceuticals, Ltd.
2441	vatiquinone	Vincerinone	11/17/2014	Treatment of Rett syndrome	Edison pharmaceuticals, Inc.
2442	(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride	n/a	5/18/2016	Treatment of Rett Syndrome.	Anavex Life Sciences Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2443	mecasermin, recombinant human insulin-like growth factor-1	Increlex	9/21/2015	Treatment of Rett Syndrome.	Keck Graduate Institute of Applied Life Sciences
2444	sarizotan	n/a	7/7/2015	Treatment of Rett syndrome.	Newron Pharmaceuticals US, Inc.
2445	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
2446	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
2447	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	6/13/2016	Treatment of sarcoidosis.	Araim Pharmaceuticals, Inc.
2448	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	Mondobiotech Laboratories AG
2449	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD
2450	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.
2451	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune
2452	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
2453	Eprodinate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2454	N-tert-butyl-3-[5-methyl-2-{{4-(2-pyrididin-1-ylethoxy)phenyl}amino}pyrimidin-4-yl-amino] benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
2455	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
2456	midazolam	n/a	2/8/2016	Treatment of seizures induced by organophosphorous insecticide poisoning.	Meridian Medical Technologies, Inc.
2457	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
2458	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
2459	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
2460	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/2015	Treatment of severe combined immune deficiency-X1	Boston Children's Hospital

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2461	autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
2462	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
2463	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company
2464	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
2465	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
2466	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
2467	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe preeclampsia	Salupont Consulting Ltd
2468	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Velo Bio, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2469	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
2470	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
2471	docosahexaenoic acid	n/a	6/1/2015	Treatment of short bowel syndrome	Sancilio and Company, Inc.
2472	human insulin (rDNA)	n/a	4/6/2015	Treatment of short bowel syndrome (SBS).	Nutrinia, Ltd.
2473	recombinant fusion protein comprising exenatide and XTEN	n/a	10/7/2015	Treatment of short bowel syndrome.	NAIA Pharmaceuticals, Inc.
2474	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
2475	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
2476	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	Baxalta US, Inc.
2477	6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydropyran-4-yl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one	n/a	9/4/2014	Treatment of sickle cell disease	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2478	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
2479	docosahexaenoic acid	n/a	4/27/2015	Treatment of sickle cell disease	Sancilio & Company, Inc.
2480	dodecafluoropentane emulsion	n/a	2/11/2016	Treatment of sickle cell disease	NuvOx Pharma
2481	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
2482	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
2483	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
2484	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2485	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
2486	prasugrel hydrochloride	Effient	5/26/2015	Treatment of sickle cell disease	Eli Lilly
2487	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
2488	sevuparin	n/a	3/17/2015	Treatment of sickle cell disease	Dilaforette AB
2489	2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	n/a	12/29/2015	Treatment of sickle cell disease (SCD).	Global Blood Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2490	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
2491	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
2492	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
2493	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAGEN Inc.
2494	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
2495	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
2496	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2497	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2498	mebendazole	Vermox 500 Mg Chewable Tablets	9/3/2014	Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).	Janssen Pharmaceutical Research & Development, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2499	udenafil	n/a	8/31/2015	Treatment of single ventricle congenital heart disease with Fontan physiology	Mezzion Pharma Co. Ltd.
2500	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
2501	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.
2502	aldoxorubicin	n/a	9/24/2014	Treatment of small cell lung cancer	CytRx Corporation
2503	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
2504	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
2505	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
2506	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
2507	rovalpituzumab tesirine	n/a	12/22/2015	Treatment of small cell lung cancer	AbbVie Stemcentrx, LLC
2508	sacituzumab govitecan	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, Inc.
2509	tarextumab	n/a	1/26/2015	Treatment of small cell lung cancer	OncoMed Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2510	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc
2511	7-ethyl-10-hydroxycamptothecin (EHC)	n/a	4/13/2016	Treatment of small cell lung cancer.	Nippon Kayaku Co., Ltd.
2512	nivolumab	n/a	9/15/2015	Treatment of small cell lung cancer.	Bristol-Myers Squibb Company
2513	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab') ₂ bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
2514	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2515	ifosfamide	n/a	8/7/1985	Treatment of soft tissue and bone sarcomas	Bristol-Myers Squibb Company
2516	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
2517	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2518	5-imino-13-deoxydoxorubicin HCl	n/a	12/31/2015	Treatment of soft tissue sarcoma	Gem Pharmaceuticals, LLC
2519	combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)	n/a	5/2/2016	Treatment of soft tissue sarcoma	Immune Design Corp.
2520	crenolanib	n/a	3/18/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
2521	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics
2522	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
2523	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
2524	olaratumab	n/a	10/9/2014	Treatment of soft tissue sarcoma	Eli Lilly and Company
2525	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2526	selinexor	n/a	7/7/2016	Treatment of soft tissue sarcoma	Karyopharm Therapeutics, Inc.
2527	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
2528	(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	n/a	8/31/2015	Treatment of soft tissue sarcoma.	Loxo Oncology, Inc.
2529	Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against the NY-ESO-1 protein	n/a	3/28/2016	Treatment of soft tissue sarcoma.	Adaptimmune, LLC
2530	dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
2531	Human/Murine Chimeric Monoclonal antibody to Endoglin	n/a	1/20/2016	Treatment of soft tissue sarcoma.	Tracon Pharmaceuticals, Inc.
2532	recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A	n/a	1/6/2016	Treatment of soft tissue sarcoma.	Immune Design Corp.
2533	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	SimRx Advisors LLC
2534	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2535	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
2536	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.
2537	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG
2538	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
2539	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)
2540	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
2541	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
2542	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.
2543	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
2544	L-baclofen	n/a	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2545	1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]	n/a	2/17/2016	Treatment of spinal and bulbar muscular atrophy	Allianz Pharmascience Ltd.
2546	trehalose	n/a	11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	BioBlast Pharma Ltd
2547	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
2548	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	CureSMA
2549	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/2014	Treatment of spinal muscular atrophy	AveXis, Inc.
2550	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
2551	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
2552	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2553	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
2554	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2555	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
2556	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
2557	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Genentech, Inc.
2558	riluzole	n/a	2/23/2016	Treatment of spinocerebellar ataxia.	Biohaven Pharmaceutical Holding Company, Ltd.
2559	2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride	n/a	5/18/2016	Treatment of spinocerebellar ataxia.	Biohaven Pharmaceuticals, Inc.
2560	ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Pharmacyclics, LLC
2561	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
2562	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2563	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
2564	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
2565	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
2566	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
2567	177-LU-DOTA-GlyGlyNle-CycMSHhex	n/a	4/16/2015	Treatment of Stage IIB through IV malignant melanoma	SolaranRx, Inc.
2568	cenersen	Aezea	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
2569	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
2570	Adenovirus encoding the recombinant CD40 ligand	n/a	4/19/2016	Treatment of stage IIb through IV melanoma.	Memgen LLC
2571	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2572	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
2573	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
2574	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Oncotelic, Inc.
2575	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
2576	bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
2577	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
2578	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
2579	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
2580	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune
2581	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
2582	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2583	6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
2584	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Array BioPharmas, Inc.
2585	epacadostat	n/a	2/11/2016	Treatment of stage IIB-IV melanoma.	Incyte Corporation
2586	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
2587	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIb through IV metastatic melanoma	Caladrius Biosciences
2588	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2589	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
2590	ABCA4 DNA nanoparticles	n/a	10/28/2015	Treatment of Stargardt Macular Degeneration	Copernicus Therapeutics, Inc.
2591	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
2592	echothiophate iodide	n/a	6/2/2014	Treatment of Stargardt's disease	Makindus, Inc.
2593	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy	Astellas Pharma Global Development Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2594	1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	n/a	7/7/2016	Treatment of status epilepticus	Bio-Pharm Solutions Co., Ltd.
2595	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics
2596	midazolam	n/a	2/4/2016	Treatment of status epilepticus	Meridian Medical Technologies, Inc.
2597	midazolam	n/a	2/18/2016	Treatment of status epilepticus	Shire Development LLC
2598	ganaxolone	n/a	4/14/2016	Treatment of status epilepticus.	Marinus Pharmaceuticals, Inc.
2599	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.
2600	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
2601	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
2602	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
2603	interleukin-1 receptor antagonist anakinra	Kineret	9/15/2015	Treatment of Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease.	Swedish Orphan Biovitrum AB
2604	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2605	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
2606	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-lys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
2607	intraventricular nimodipine	n/a	5/28/2015	Treatment of subarachnoid hemorrhage	Edge Therapeutics, Inc.
2608	stabilized sulforaphane	n/a	8/22/2016	Treatment of subarachnoid hemorrhage	Evgen Pharma PLC
2609	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals
2610	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
2611	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
2612	pleconaril	n/a	12/22/2014	Treatment of symptomatic enteroviral infection in the neonate	AntiVirus Therapeutics, Inc.
2613	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Lithera, Inc.
2614	S-ethylisothiourea diethylphosphate	n/a	8/29/2016	Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period.	TrioxBio, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2615	6-[[[(1S)-1-phenylethyl]amino]-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione	n/a	4/27/2016	Treatment of symptomatic obstructive hypertrophic cardiomyopathy	MyoKardia, Inc.
2616	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm3.	EMD Serono, Inc.
2617	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
2618	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
2619	hydroxyurea	Pedroxa	3/16/2015	Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.	Ebelle D'Ebelle Pharmaceuticals LLC
2620	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
2621	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2622	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2623	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	MeiraGTx, LLC
2624	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
2625	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
2626	2,2'-{2-[1R)-1-(((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
2627	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.
2628	(6aR, 10aR)-3-(1,1-dimethylheptyl)-8-tetrahydro-cannabinol-9-carboxylic acid	n/a	6/10/2015	Treatment of systemic sclerosis	Corbus Pharmaceuticals, Inc.
2629	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	n/a	3/31/2015	Treatment of systemic sclerosis	Inventiva Pharma
2630	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2631	high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein	n/a	6/27/2016	Treatment of systemic sclerosis	iBio, Inc.
2632	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
2633	monoclonal antibody targeting eotaxin-2	n/a	1/6/2015	Treatment of systemic sclerosis	ChemomAb, Ltd.
2634	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
2635	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
2636	riociguat	Adempas	7/24/2014	Treatment of systemic sclerosis	Bayer HealthCare Pharmaceuticals
2637	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Medac GmbH
2638	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
2639	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Genentech, Inc.
2640	nintedanib	n/a	7/6/2016	Treatment of systemic sclerosis (including the associated interstitial lung disease).	Boehringer Ingelheim Pharmaceuticals, Inc.
2641	(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)	n/a	10/14/2015	Treatment of systemic sclerosis.	Genkyotex Innovation SAS

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2642	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
2643	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
2644	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2645	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
2646	Tretinoin	Atra-lv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
2647	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
2648	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech
2649	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
2650	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2651	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
2652	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.
2653	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
2654	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
2655	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation
2656	pegylated carboxyhemoglobin bovine	Sanguinate	1/15/2015	Treatment of the comorbidities associated with Sickle Cell Disease	Prolong Pharmaceuticals, LLC
2657	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease, type C.	Actelion Pharmaceuticals Ltd
2658	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
2659	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2660	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
2661	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.
2662	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
2663	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2664	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.
2665	Caplacizumab	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
2666	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
2667	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2668	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxalta US Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2669	anfibatide	n/a	3/10/2016	Treatment of thrombotic thrombocytopenic purpura.	Lee's Pharmaceutical (Hong Kong) Limited
2670	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
2671	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Tiziana Life Sciences PLC
2672	deoxythymidine monophosphate and deoxycytidine monophosphate	n/a	7/7/2016	Treatment of thymidine kinase 2 deficiency.	Columbia University Medical Center
2673	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
2674	deutetrabenazine	n/a	1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	TEVA Pharmaceuticals
2675	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
2676	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2677	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL
2678	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2679	revusiran	n/a	5/18/2015	Treatment of transthyretin amyloidosis	Alnylam Pharmaceuticals, Inc.
2680	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
2681	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	SyneuRx International Corp.
2682	(5R)-5-(4-([2-fluorophenyl)methyl]oxy)phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.
2683	carbon dioxide	n/a	12/17/2015	Treatment of trigeminal neuralgia	Capnia, Inc.
2684	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
2685	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
2686	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
2687	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/3/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer	Ignyta, Inc.
2688	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/12/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer	Ignyta, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2689	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis	Global Alliance for TB Drug Development
2690	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2691	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
2692	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.
2693	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
2694	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	Oncolmmune, Inc.
2695	cannabidiol	n/a	4/19/2016	Treatment of tuberous sclerosis complex.	GW Pharma Ltd.
2696	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC
2697	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
2698	alpha1-proteinase inhibitor (human)	Prolastin(R)-C	3/3/2015	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Grifols Therapeutics, Inc.
2699	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2700	autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells	n/a	5/10/2016	Treatment of type 1 diabetes mellitus with residual beta cell function	Caladrius Biosciences
2701	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
2702	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
2703	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
2704	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
2705	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
2706	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
2707	Roseburia hominis	Rosburix	8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	4D Pharma Research Ltd
2708	dihydroartemisinin and piperaquine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2709	gemcitabine	n/a	12/30/2015	Treatment of upper tract urothelial carcinoma	TARIS Biomedical LLC
2710	mitomycin	Mitogel	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	TheraCoat, Ltd.
2711	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2712	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
2713	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Promethera Biosciences S.A./N.V.
2714	live E. coli Nissle bacterium modified to assimilate ammonia	n/a	8/22/2016	Treatment of urea cycle disorders	Synlogic, Inc.
2715	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2716	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2717	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
2718	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company
2719	modified human papillomavirus capsid protein conjugated to a near infrared dye	n/a	4/8/2015	Treatment of uveal melanoma	Aura Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2720	HLA-A2-selective gp100-specific T cell redirector	n/a	1/21/2016	Treatment of uveal melanoma.	Immunocore Ltd
2721	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals
2722	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
2723	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
2724	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
2725	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
2726	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	Santen SAS
2727	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.
2728	recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	ARCA Biopharma, Inc.
2729	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
2730	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2731	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
2732	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
2733	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
2734	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
2735	von Willebrand Factor Human Concentrate	Wilfactin	5/29/2014	Treatment of Von Willebrand Disease	rEVO Biologics, Inc.
2736	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
2737	(S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)-imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)-benzamide	n/a	10/22/2015	Treatment of Waldenstrom macroglobulinemia.	Acerta Pharma BV
2738	(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide	n/a	6/29/2016	Treatment of Waldenstrom's macroglobulinemia	BeiGene USA, Inc.
2739	antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9	n/a	12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Idera Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2740	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.
2741	oprozomib	n/a	8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Onyx Therapeutics, Inc.
2742	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.
2743	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
2744	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
2745	trientine tetrahydrochloride	n/a	3/10/2016	treatment of Wilson's disease	GMP-Orphan SAS
2746	Ammonium tetrathiomolybdate	Coprexia	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
2747	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB
2748	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	GlaxoSmithKline Intellectual Property Development

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2749	dantrolene sodium	n/a	2/17/2016	Treatment of Wolfram Syndrome	Washington University in St. Louis
2750	sodium valproate	n/a	8/5/2015	Treatment of Wolfram syndrome	The University of Birmingham
2751	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2752	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	NeuroVia, Inc.
2753	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
2754	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.
2755	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLR5).	Applied Genetic Technologies Corporation
2756	non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene	At001	12/3/2014	Treatment of x-linked myotubular myopathy	Audentes Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2757	adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS)	n/a	11/16/2015	Treatment of X-linked retinoschisis	Paul A. Sievig, MD, PhD, National Eye Institute, NIH
2758	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
2759	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
2760	5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide	n/a	1/15/2015	Treatment pulmonary arterial hypertension	Gilead Sciences, Inc.
2761	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Array BioPharma, Inc.
2762	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	6/13/2016	Treatment to increase survival and improve functioning of pancreatic islets following transplantation	Araim Pharmaceuticals, Inc.
2763	low molecular weight dextran sulfate	Ibsolvir(R)	7/6/2011	Treatment to mobilize progenitor cells prior to stem cell transplantation	TikoMed AB
2764	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2765	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
2766	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
2767	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	CMC Contrast AB
2768	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2769	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2770	spironolactone	Aldactone	5/22/2014	Use in pediatric patients with primary hyperaldosteronism	CMP Pharma, Inc.
2771	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Gliotherapy, Ltd.
2772	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
2773	Somatrem for injection	Protropin	12/9/1985	1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000).	Genentech, Inc.
2774	Potassium citrate	Urocit-K	11/1/1984	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2775	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages.	Glaxo Wellcome Inc.
2776	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Novo Nordisk Pharmaceuticals
2777	Sotalol HCl	Betapace	9/23/1988	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treating ventricular tachyarrhythmias	Berlex Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2778	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
2779	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Wellstat Therapeutics Corp.
2780	Pentastarch	Pentaspán	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	DuPont Pharmaceuticals
2781	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation
2782	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
2783	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2784	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
2785	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.
2786	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Horizon Pharma Ireland Limited
2787	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
2788	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2789	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	Netspot	12/31/2013	Diagnostic for the clinical management of neuroendocrine tumors	Advanced Accelerator Applications, USA
2790	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	ImmunexImmunex
2791	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
2792	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2793	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.
2794	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
2795	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.
2796	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
2797	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
2798	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2799	chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age	Solvay
2800	human monoclonal anti-PA antibody	Yervoy	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
2801	Aprotinin	Trasylol	11/17/1993	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	Bayer Corporation
2802	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2803	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
2804	Protein C concentrate	Ceprotin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxalta US, Inc.
2805	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
2806	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
2807	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
2808	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2809	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
2810	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
2811	Antihemophilic factor (recombinant)	Refacto, Xyntha	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
2812	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
2813	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
2814	lobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2815	Follitropin alfa, recombinant	Gonal-F	12/21/1998	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	EMD Serono, Inc.
2816	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
2817	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2818	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals
2819	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.
2820	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn
2821	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
2822	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
2823	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Chiesi USA, Inc.
2824	defibrotide	Defitelio	5/21/2003	For the treatment of hepatic veno-occlusive disease	Jazz Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2825	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
2826	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
2827	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	iPR Pharmaceuticals, Inc.
2828	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
2829	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
2830	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2831	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation
2832	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
2833	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
2834	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
2835	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
2836	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2837	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
2838	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
2839	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
2840	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
2841	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2842	Corticotropin ovine trifluoracetate	Actrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	Ferring Laboratories, Inc.
2843	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
2844	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2845	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
2846	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
2847	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2848	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2849	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.
2850	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.
2851	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2852	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2853	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2854	melphalan	Evomela	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
2855	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
2856	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
2857	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
2858	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2859	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
2860	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Horizon Pharma, Inc.
2861	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
2862	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
2863	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc
2864	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.
2865	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2866	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
2867	acetylcysteine effervescent tablets for oral solution	Cetylev	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Arbor Pharmaceuticals, Inc.
2868	C1-esterase-inhibitor, human, pasteurized	Berinert	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
2869	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
2870	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
2871	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
2872	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.
2873	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
2874	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2875	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
2876	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
2877	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development
2878	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
2879	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
2880	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
2881	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2882	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
2883	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
2884	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxalta US, Inc.
2885	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
2886	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2887	tacrolimus	Envarsus Xr	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
2888	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
2889	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
2890	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
2891	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
2892	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2893	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
2894	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
2895	raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
2896	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
2897	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
2898	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
2899	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxalta US, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2900	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV
2901	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.
2902	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Horizon Pharma Rheumatology, LLC
2903	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
2904	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation
2905	idarucizumab	n/a	5/28/2015	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Boehringer Ingelheim Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2906	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
2907	antihemophilic factor (recombinant), porcine sequence	Obizur	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxalta US, Inc.
2908	calfactant	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
2909	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Novartis Pharmaceuticals Corp.
2910	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
2911	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2912	C1-esterase inhibitor (recombinant)	Ruconest	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Santarus, Inc.
2913	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
2914	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
2915	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation
2916	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2917	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
2918	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	SERB, S.A.
2919	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
2920	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
2921	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
2922	vinCRISTine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
2923	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Novartis Pharmaceuticals Corp.
2924	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
2925	blinatumomab	Blinicyto	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen, Inc.
2926	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2927	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Baxalta US, Inc.
2928	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
2929	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories
2930	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
2931	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
2932	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
2933	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
2934	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.
2935	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
2936	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2937	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
2938	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
2939	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
2940	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
2941	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
2942	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
2943	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
2944	alectinib	Alecensa	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Genentech, Inc.
2945	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
2946	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
2947	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
2948	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2949	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
2950	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
2951	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	Shire
2952	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.
2953	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.
2954	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
2955	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Clinigen Healthcare Ltd.
2956	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2957	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Novartis Pharmaceuticals Corp.
2958	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
2959	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
2960	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
2961	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.
2962	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2963	coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk Inc.
2964	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
2965	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
2966	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
2967	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation
2968	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
2969	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
2970	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
2971	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2972	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2973	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.
2974	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.
2975	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
2976	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
2977	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
2978	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
2979	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Horizon Pharma Ireland Limited
2980	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
2981	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.
2982	deferasirox	Exjade	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Novartis Pharmaceuticals Corporation
2983	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2984	bendamustine for 50 ml admixture	Bendeka	7/2/2014	Treatment of chronic lymphocytic leukemia	Eagle Pharmaceuticals, INC.
2985	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
2986	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2987	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
2988	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
2989	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
2990	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
2991	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2992	venetoclax	Venclexta	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc
2993	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, LLC
2994	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, LLC
2995	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, LLC
2996	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2997	idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc.
2998	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
2999	bosutinib	Bosulf	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
3000	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
3001	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
3002	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
3003	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
3004	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
3005	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
3006	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
3007	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
3008	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3009	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
3010	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
3011	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
3012	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
3013	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.
3014	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	Photrex Viscous	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
3015	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
3016	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
3017	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
3018	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3019	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
3020	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
3021	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
3022	lumacaftor/ivacaftor	Orkambi	6/30/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
3023	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
3024	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
3025	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
3026	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation
3027	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
3028	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
3029	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3030	Antivenin crotaline (pit-viper) equine immune F(ab)2)	Anavip	1/29/2004	Treatment of envenomation by Crotaline snakes	Rare Disease Therapeutics, Inc.
3031	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.
3032	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
3033	gefitinib	Iressa	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
3034	osimertinib	Tagrisso	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
3035	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
3036	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
3037	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
3038	obiltoxaximab	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
3039	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3040	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Genentech, Inc.
3041	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
3042	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients.	CSL Behring, LLC
3043	idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
3044	obinutuzumab	Gazyva	4/15/2015	Treatment of follicular lymphoma	Genentech, Inc.
3045	bendamustine for 50ml admixture	Bendeka	7/2/2014	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Eagle Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3046	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
3047	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.
3048	lenvatinib	Lenvima	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.
3049	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
3050	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
3051	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3052	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
3053	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
3054	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd
3055	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
3056	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
3057	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
3058	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
3059	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
3060	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
3061	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
3062	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmed, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3063	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
3064	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
3065	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
3066	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.
3067	antihemophilic factor (recombinant), Fc fusion protein	Eloctate	11/23/2010	Treatment of hemophilia A	Biogen Idec Inc.
3068	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
3069	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
3070	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
3071	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
3072	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3073	methylene blue0.5%	Provayblue	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
3074	Human factor X	Coagadex	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
3075	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
3076	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
3077	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Company
3078	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Company
3079	nivolumab	Opdivo	8/7/2014	Treatment of Hodgkin lymphoma	Bristol-Myers Squibb Co.
3080	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
3081	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
3082	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
3083	evolocumab	Repatha	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
3084	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3085	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Kastle Therapeutics, LLC
3086	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
3087	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc
3088	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Amedra Pharmaceuticals LLC
3089	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia in malignancy	Amgen, Inc.
3090	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
3091	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3092	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
3093	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
3094	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical, Inc.
3095	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
3096	parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	Shire-NPS Pharmaceuticals, Inc.
3097	Asfotase alfa	Strensiq	9/12/2008	Treatment of hypophosphatasia	Alexion Pharmaceuticals, Inc.
3098	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3099	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
3100	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
3101	pirfenidone	Esbriet	3/5/2004	Treatment of idiopathic pulmonary fibrosis	Genentech
3102	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	Novartis Pharmaceuticals Corp.
3103	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory
3104	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
3105	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
3106	cholic acid	Cholbam	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Retrophin, Inc.
3107	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services
3108	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3109	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
3110	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of inhalational anthrax	Cangene Corp. - Emergent Biosolutions
3111	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
3112	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
3113	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
3114	isavuconazonium sulfate	Cresemba	5/6/2013	Treatment of invasive aspergillosis	Astellas Pharma Global Development Inc.
3115	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
3116	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
3117	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.
3118	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3119	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
3120	riboflavin ophthalmic solution & ultraviolet A	Photrex Viscous	9/2/2011	Treatment of keratoconus	Avedro, Inc.
3121	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
3122	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.
3123	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
3124	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Knight Therapeutics (USA)
3125	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
3126	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
3127	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
3128	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
3129	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3130	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
3131	sirolimus	Rapamune	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
3132	sebelipase alfa	Kanuma	7/1/2010	Treatment of lysosomal acid lipase deficiency	Alexion Pharmaceuticals
3133	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
3134	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
3135	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
3136	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
3137	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
3138	dantrolene sodium suspension for injection	Ryanodex	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
3139	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3140	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
3141	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
3142	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
3143	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
3144	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Pharmacyclics, LLC
3145	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
3146	bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
3147	bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
3148	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
3149	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
3150	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Aegerion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3151	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
3152	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
3153	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
3154	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
3155	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.
3156	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
3157	adalimumab	Humira	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	AbbVie, Inc.
3158	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
3159	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxalta US, Inc.
3160	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
3161	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3162	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
3163	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
3164	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
3165	ixazomib citrate	Ninlaro	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
3166	lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Celgene Corporation
3167	lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Celgene Corporation
3168	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
3169	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
3170	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
3171	daratumumab	Darzalex	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
3172	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
3173	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
3174	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3175	meclorethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.
3176	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
3177	decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Otsuka Pharmaceutical Development
3178	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
3179	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
3180	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
3181	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
3182	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
3183	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
3184	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Ross Laboratories
3185	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome	Ross Laboratories

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3186	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
3187	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
3188	dinutuximab	Unituxin	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
3189	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	Amedra Pharmaceuticals LLC
3190	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
3191	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
3192	lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Ipsen Biopharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3193	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Lundbeck LLC
3194	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
3195	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
3196	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
3197	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation
3198	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
3199	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
3200	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3201	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
3202	afatinib	Gilotrif(R)	8/3/2015	Treatment of non-small cell lung cancer with squamous histology.	Boehringer Ingelheim Pharmaceuticals, Inc.
3203	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
3204	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
3205	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
3206	olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
3207	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
3208	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
3209	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
3210	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
3211	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3212	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.
3213	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
3214	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
3215	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
3216	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.
3217	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (\geq 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3218	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
3219	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Idelvion	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring, LLC
3220	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
3221	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
3222	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical
3223	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	Genzyme Corporation
3224	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3225	nintedanib	Ofev	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim Pharmaceuticals, Inc.
3226	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
3227	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
3228	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeitische Fabrik GMBH & Co, KG
3229	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
3230	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
3231	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3232	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
3233	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc.
3234	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
3235	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Shire
3236	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
3237	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
3238	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
3239	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
3240	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
3241	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3242	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.
3243	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
3244	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
3245	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Spectrum Pharmaceuticals, Inc.
3246	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.
3247	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
3248	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
3249	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
3250	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
3251	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3252	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.
3253	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
3254	ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation
3255	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	Arbor Pharmaceuticals, LLC
3256	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
3257	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
3258	obeticholic acid	Ocaliva	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
3259	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals
3260	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
3261	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
3262	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3263	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
3264	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
3265	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
3266	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd
3267	selexipag	Uptravi	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
3268	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
3269	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
3270	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.
3271	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
3272	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
3273	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
3274	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
3275	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3276	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
3277	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
3278	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
3279	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
3280	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
3281	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
3282	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
3283	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
3284	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
3285	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3286	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
3287	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
3288	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
3289	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
3290	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
3291	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn
3292	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company
3293	ibrutinib	Imbruvica	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, LLC
3294	eribulin mesylate	Halaven	5/14/2012	Treatment of soft tissue sarcoma	Eisai Inc.
3295	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Janssen Research & Development, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3296	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	Novartis Pharmaceuticals Corp
3297	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
3298	necitumumab	n/a	11/20/2015	Treatment of squamous non-small cell lung cancer	Eli Lilly and Company
3299	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
3300	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
3301	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	Novartis Pharmaceuticals Corp.
3302	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	Novartis Pharmaceuticals Corp.
3303	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	Novartis Pharmaceuticals Corp.
3304	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
3305	Combination of nivolumab and ipilimumab	n/a	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Bristol-Myers Squibb Company
3306	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3307	talimogene laherparepvec	Imlygic	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc. (subsidiary of Amgen)
3308	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
3309	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
3310	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
3311	filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
3312	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
3313	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
3314	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation
3315	pralatrexate	Folotylin	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.
3316	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3317	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
3318	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
3319	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
3320	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation
3321	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development
3322	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
3323	Aminosalicilic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3324	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
3325	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
3326	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
3327	eliglustat	Cerdelga	9/17/2008	Treatment of Type I Gaucher disease	Genzyme Corporation
3328	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB
3329	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3330	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and argininosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
3331	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
3332	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
3333	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
3334	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
3335	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxalta US, Inc.
3336	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.
3337	ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, LLC

Orphan Drug Designations and Approvals List as of 09-01-2016
Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3338	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
3339	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
3340	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
3341	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.
3342	isavuconazonium sulfate	Cresemba	10/25/2013	Treatment of zygomycosis	Astellas Pharma Global Development Inc.
3343	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
3344	technetium Tc 99m tilmanocept	Lymphoseek	9/17/2014	Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck	Navidea Biopharmaceuticals
3345	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.

Orphan Drug Designations and Approvals List as of 09-01-2016

Governs October 1, 2016 - December 31, 2016

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
3346	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.